Danaher (DHR) 10-Q23 Oct 232023 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 29, 2023	Oct. 19, 2023
Entity Information [Line Items]
Document type	10-Q
Document quarterly report	true
Document period end date	Sep. 29, 2023
Document transition report	false
Entity file number	001-08089
Entity registrant name	DANAHER CORPORATION
Entity incorporation, state code	DE
Entity tax identification number	59-1995548
Entity address, address line one	2200 Pennsylvania Avenue, N.W., Suite 800W
Entity address, postal zip code	20037-1701
Entity address, city	Washington,
Entity address, state	DC
City area code	202
Local phone number	828-0850
Entity current reporting status	Yes
Entity interactive data current	Yes
Entity filer category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
Entity shell company	false
Entity common stock, shares outstanding		738,927,107
Amendment flag	false
Document fiscal year focus	2023
Document fiscal period focus	Q3
Current fiscal year end date	--12-31
Entity central index key	0000313616
Common stock
Entity Information [Line Items]
Title of 12(b) security	Common stock, $0.01 par value
Trading symbol	DHR
Security exchange name	NYSE
1.700% Senior Notes due 2024
Entity Information [Line Items]
Title of 12(b) security	1.700% Senior Notes due 2024
Trading symbol	DHR 24
Security exchange name	NYSE
0.200% Senior Notes due 2026
Entity Information [Line Items]
Title of 12(b) security	0.200% Senior Notes due 2026
Trading symbol	DHR/26
Security exchange name	NYSE
2.100% Senior Notes due 2026
Entity Information [Line Items]
Title of 12(b) security	2.100% Senior Notes due 2026
Trading symbol	DHR 26
Security exchange name	NYSE
1.200% Senior Notes due 2027
Entity Information [Line Items]
Title of 12(b) security	1.200% Senior Notes due 2027
Trading symbol	DHR/27
Security exchange name	NYSE
0.450% Senior Notes due 2028
Entity Information [Line Items]
Title of 12(b) security	0.450% Senior Notes due 2028
Trading symbol	DHR/28
Security exchange name	NYSE
2.500% Senior Notes due 2030
Entity Information [Line Items]
Title of 12(b) security	2.500% Senior Notes due 2030
Trading symbol	DHR 30
Security exchange name	NYSE
0.750% Senior Notes due 2031
Entity Information [Line Items]
Title of 12(b) security	0.750% Senior Notes due 2031
Trading symbol	DHR/31
Security exchange name	NYSE
1.350% Senior Notes due 2039
Entity Information [Line Items]
Title of 12(b) security	1.350% Senior Notes due 2039
Trading symbol	DHR/39
Security exchange name	NYSE
1.800% Senior Notes due 2049
Entity Information [Line Items]
Title of 12(b) security	1.800% Senior Notes due 2049
Trading symbol	DHR/49
Security exchange name	NYSE

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 29, 2023	Dec. 31, 2022
Current assets:
Cash and equivalents	$ 12,277	$ 5,995
Trade accounts receivable, less allowance for doubtful accounts of $136 and $126, respectively	4,201	4,918
Inventories:
Finished goods	1,447	1,504
Work in process	497	473
Raw materials	1,080	1,133
Total inventories	3,024	3,110
Prepaid expenses and other current assets	1,703	1,860
Total current assets	21,205	15,883
Property, plant and equipment, net of accumulated depreciation of $4,122 and $3,893, respectively	4,302	3,956
Other long-term assets	4,286	4,459
Goodwill	39,155	39,752
Other intangible assets, net	18,786	20,300
Total assets	87,734	84,350
Current liabilities:
Notes payable and current portion of long-term debt	2,547	591
Trade accounts payable	1,894	2,296
Accrued expenses and other liabilities	4,926	5,502
Total current liabilities	9,367	8,389
Other long-term liabilities	6,439	6,785
Long-term debt	19,513	19,086
Stockholders’ equity:
Preferred stock	0	1,668
Common stock	9	9
Additional paid-in capital	14,085	12,072
Retained earnings	42,272	39,205
Accumulated other comprehensive income (loss)	(3,959)	(2,872)
Total Danaher stockholders’ equity	52,407	50,082
Noncontrolling interests	8	8
Total stockholders’ equity	52,415	50,090
Total liabilities and stockholders’ equity	$ 87,734	$ 84,350

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Sep. 29, 2023
Allowance for doubtful accounts	$ 126	$ 136
Property, plant and equipment, accumulated depreciation	$ 3,893	$ 4,122
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, shares issued (in shares)	869,300,000	880,200,000
Common stock, shares outstanding (in shares)	728,300,000	738,900,000
Preferred stock
Preferred stock, no par value (in usd per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock \| Series B Preferred Stock
Preferred stock, shares issued (in shares)	1,720,000	0
Preferred stock, shares outstanding (in shares)	1,720,000	0
Preferred stock, dividend rate, percent	5%

Consolidated Condensed Statemen

Consolidated Condensed Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Income Statement [Abstract]
Sales	$ 6,873	$ 7,663	$ 21,197	$ 23,102
Cost of sales	(2,873)	(3,079)	(8,786)	(9,092)
Gross profit	4,000	4,584	12,411	14,010
Operating costs:
Selling, general and administrative expenses	(2,145)	(2,149)	(6,486)	(6,326)
Research and development expenses	(417)	(420)	(1,264)	(1,292)
Operating profit	1,438	2,015	4,661	6,392
Nonoperating income (expense):
Other income (expense), net	(47)	(51)	(52)	(158)
Interest expense	(73)	(42)	(208)	(147)
Interest income	79	9	186	12
Earnings before income taxes	1,397	1,931	4,587	6,099
Income taxes	(268)	(359)	(902)	(1,122)
Net earnings	1,129	1,572	3,685	4,977
Mandatory convertible preferred stock dividends	0	(21)	(21)	(84)
Net earnings attributable to common stockholders	$ 1,129	$ 1,551	$ 3,664	$ 4,893
Net earnings per common share:
Basic (in usd per share)	$ 1.53	$ 2.13	$ 4.98	$ 6.76
Diluted (in usd per share)	$ 1.51	$ 2.10	$ 4.94	$ 6.67	[1]
Average common stock and common equivalent shares outstanding:
Basic (in shares)	739.4	728.5	735.4	723.8
Diluted (in shares)	745.9	737.4	742.1	737

[1]Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,129	$ 1,572	$ 3,685	$ 4,977
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	(303)	(1,039)	(982)	(2,824)
Pension and postretirement plan benefit adjustments	1	7	1	28
Cash flow hedge adjustments	(81)	(77)	(106)	(31)
Total other comprehensive income (loss), net of income taxes	(383)	(1,109)	(1,087)	(2,827)
Comprehensive income	$ 746	$ 463	$ 2,598	$ 2,150

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Preferred stock	Common stock	Additional paid-in capital	Additional paid-in capital Preferred stock	Retained earnings	Accumulated other comprehensive income (loss)	Noncontrolling interests
Balance, beginning of period at Dec. 31, 2021		$ 3,268	$ 9	$ 10,090		$ 32,827	$ (1,027)	$ 10
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Mandatory Convertible Preferred Stock to common stock and Common stock issued in connection with Mandatory Convertible Preferred Stock conversions		(1,600)			$ 1,600
Common stock-based award				309
Acquisition of noncontrolling interests				(14)
Net earnings	$ 4,977					4,977
Common stock dividends declared						(543)
Mandatory Convertible Preferred Stock dividends declared						(84)
Other comprehensive income (loss)	(2,827)						(2,827)
Change in noncontrolling interests								(2)
Balance, end of period at Sep. 30, 2022	46,993	1,668	9	11,985		37,177	(3,854)	8
Balance, beginning of period at Jul. 01, 2022		1,668	9	11,854		35,808	(2,745)	7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Mandatory Convertible Preferred Stock to common stock and Common stock issued in connection with Mandatory Convertible Preferred Stock conversions		0			0
Common stock-based award				131
Acquisition of noncontrolling interests				0
Net earnings	1,572					1,572
Common stock dividends declared						(182)
Mandatory Convertible Preferred Stock dividends declared						(21)
Other comprehensive income (loss)	(1,109)						(1,109)
Change in noncontrolling interests								1
Balance, end of period at Sep. 30, 2022	46,993	1,668	9	11,985		37,177	(3,854)	8
Balance, beginning of period at Dec. 31, 2022	50,090	1,668	9	12,072		39,205	(2,872)	8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Mandatory Convertible Preferred Stock to common stock and Common stock issued in connection with Mandatory Convertible Preferred Stock conversions		(1,668)			1,668
Common stock-based award				345
Acquisition of noncontrolling interests				0
Net earnings	3,685					3,685
Common stock dividends declared						(597)
Mandatory Convertible Preferred Stock dividends declared						(21)
Other comprehensive income (loss)	(1,087)						(1,087)
Change in noncontrolling interests								0
Balance, end of period at Sep. 29, 2023	52,415	0	9	14,085		42,272	(3,959)	8
Balance, beginning of period at Jun. 30, 2023		0	9	13,939		41,344	(3,576)	8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Mandatory Convertible Preferred Stock to common stock and Common stock issued in connection with Mandatory Convertible Preferred Stock conversions		0			$ 0
Common stock-based award				146
Acquisition of noncontrolling interests				0
Net earnings	1,129					1,129
Common stock dividends declared						(201)
Mandatory Convertible Preferred Stock dividends declared						0
Other comprehensive income (loss)	(383)						(383)
Change in noncontrolling interests								0
Balance, end of period at Sep. 29, 2023	$ 52,415	$ 0	$ 9	$ 14,085		$ 42,272	$ (3,959)	$ 8

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net earnings	$ 3,685	$ 4,977
Noncash items:
Depreciation	526	537
Amortization of intangible assets	1,147	1,120
Stock-based compensation expense	280	270
Investment (gains) losses	58	186
Change in trade accounts receivable, net	709	(134)
Change in inventories	(25)	(729)
Change in trade accounts payable	(399)	(180)
Change in prepaid expenses and other assets	331	(104)
Change in accrued expenses and other liabilities	(767)	35
Net cash provided by operating activities	5,545	5,978
Cash flows from investing activities:
Cash paid for acquisitions	0	(304)
Payments for additions to property, plant and equipment	(981)	(823)
Proceeds from sales of property, plant and equipment	8	9
Payments for purchases of investments	(152)	(354)
Proceeds from sales of investments	33	18
All other investing activities	28	36
Total cash used in investing activities	(1,064)	(1,418)
Cash flows from financing activities:
Proceeds from the issuance of common stock in connection with stock-based compensation, net	51	15
Payment of dividends	(621)	(615)
Net proceeds from borrowings (maturities longer than 90 days)	2,605	0
Net repayments of borrowings (maturities of 90 days or less)	(9)	(719)
Net repayments of borrowings (maturities longer than 90 days)	0	(265)
All other financing activities	(53)	(80)
Total cash provided by (used in) financing activities	1,973	(1,664)
Effect of exchange rate changes on cash and equivalents	(172)	(332)
Net change in cash and equivalents	6,282	2,564
Beginning balance of cash and equivalents	5,995	2,586
Ending balance of cash and equivalents	12,277	5,150
Supplemental disclosures:
Cash interest payments	289	250
Cash income tax payments	$ 1,170	$ 1,094

General

General	9 Months Ended
General	Sep. 29, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	GENERAL The Consolidated Condensed Financial Statements included herein have been prepared by Danaher Corporation (“Danaher” or the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its consolidated subsidiaries, or the consolidated subsidiaries of Danaher Corporation, as the context requires. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The Consolidated Condensed Financial Statements included herein should be read in conjunction with the financial statements as of and for the year ended December 31, 2022 and the Notes thereto included in the Company’s 2022 Annual Report on Form 10-K filed on February 22, 2023 (the “2022 Annual Report”). In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of September 29, 2023 and December 31, 2022, its results of operations for the three and nine-month periods ended September 29, 2023 and September 30, 2022 and its cash flows for each of the nine-month periods then ended. There have been no changes to the Company’s significant accounting policies described in the Company’s 2022 Annual Report that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes. Reclassifications of certain prior year amounts have been made to conform to the current year presentation. Accounting Standards Recently Adopted —In August 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement . The ASU requires that a joint venture apply a new basis of accounting upon formation in which the joint venture will recognize and initially measure its assets and liabilities at fair value (with exceptions to fair value measurement that are consistent with the business combinations guidance). The ASU is effective prospectively for all joint venture formations with a formation date on or after January 1, 2025, with early adoption permitted. The Company early adopted the ASU effective September 30, 2023 on a prospective basis. Operating Leases —As of September 29, 2023 and December 31, 2022, operating lease right-of-use assets where the Company was the lessee were approximately $1.0 billion and are included within other long-term assets in the accompanying Consolidated Condensed Balance Sheets. The associated operating lease liabilities were approximately $1.1 billion as of September 29, 2023 and December 31, 2022, and are included in accrued expenses and other liabilities and other long-term liabilities.

Pending Acquisition

Pending Acquisition	9 Months Ended
Pending Acquisition	Sep. 29, 2023
Business Combination and Asset Acquisition [Abstract]
Pending Acquisition	PENDING ACQUISITION On August 28, 2023, the Company entered into a definitive agreement to acquire all of the outstanding shares of Abcam plc (“Abcam”) for a cash purchase price of approximately $5.7 billion, including assumed indebtedness and net of acquired cash (the “Abcam Acquisition”). Abcam is a leading global supplier of protein consumables, including highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for advancing drug discovery, life sciences research and diagnostics. Abcam generated revenues of £362 million in 2022. The Company expects to include the Abcam business within its Life Sciences segment. The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval. The Company expects to finance the Abcam Acquisition using cash on hand and/or the proceeds from the issuance of commercial paper.

Environmental & Applied Solutio

Environmental & Applied Solutions Separation	9 Months Ended
Environmental & Applied Solutions Separation	Sep. 29, 2023
Discontinued Operations and Disposal Groups [Abstract]
Environmental & Applied Solutions Separation	ENVIRONMENTAL & APPLIED SOLUTIONS SEPARATIONOn September 30, 2023 (the “Distribution Date”), the Company completed the separation (the “Separation”) of its former Environmental & Applied Solutions business by distributing to Danaher stockholders on a pro rata basis all of the issued and outstanding common stock of Veralto Corporation (“Veralto”), the entity Danaher incorporated to hold such businesses. To effect the Separation, Danaher distributed to its stockholders one share of Veralto common stock for every three shares of Danaher common stock outstanding as of September 13, 2023, the record date for the distribution. Fractional shares of Veralto common stock that otherwise would have been distributed were aggregated and sold into the public market and the proceeds distributed to Danaher stockholders who otherwise would have received fractional shares of Veralto common stock. In preparation for the Separation, in September 2023 Veralto issued approximately $2.6 billion in debt securities (refer to Note 11). The proceeds of these issuances were used to fund the approximately $2.6 billion net cash distributions Veralto made to Danaher prior to the Distribution Date. In accordance with the applicable tax rules, Danaher intends to use a portion of the cash distribution proceeds it received from Veralto to meet upcoming commercial paper and bond maturities and to use the balance of the proceeds to partially fund certain of the Company’s regular, quarterly cash dividends to shareholders. As the disposition occurred during the fourth quarter of 2023, the Company will classify Veralto as a discontinued operation in its historical financial statements beginning with the fourth quarter of 2023. The Environmental & Applied Solutions business had sales for the year ended December 31, 2022 of approximately $4.8 billion. Below is a summary of the Environmental & Applied Solutions business' sales and operating profit ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Sales $ 1,249 $ 1,208 $ 3,712 $ 3,593 Operating profit 286 286 887 829 The Company incurred separation costs of $36 million ($31 million after-tax) and $101 million ($90 million after-tax) in the three and nine-month periods ended September 29, 2023, respectively, related to preparation for the separation of the Company’s Environmental & Applied Solutions business primarily related to professional fees for legal, tax, finance, banking and information technology services and duplicative general and administrative costs. In connection with the Separation, Danaher and Veralto entered into various agreements to effect the Separation and provide a framework for their relationship after the Separation, including a separation and distribution agreement, transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement and a Danaher Business System (“DBS”) license agreement. These agreements provide for the allocation between Danaher and Veralto of assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after Veralto’s separation from Danaher and will govern certain relationships between Danaher and Veralto after the Separation.

Net Earnings Per Common Share

Net Earnings Per Common Share	9 Months Ended
Net Earnings Per Common Share	Sep. 29, 2023
Earnings Per Share [Abstract]
Net Earnings Per Common Share	NET EARNINGS PER COMMON SHARE Basic net earnings per common share (“EPS”) is calculated by taking net earnings less the Mandatory Convertible Preferred Stock (“MCPS”) dividends divided by the weighted average number of common shares outstanding for the applicable period. Diluted net EPS is computed by taking net earnings less the MCPS dividends divided by the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the three-month periods ended September 29, 2023 and September 30, 2022, approximately 2.5 million and 538 thousand options, respectively, and for the nine-month periods ended September 29, 2023 and September 30, 2022, approximately 3.2 million and 1.1 million options, respectively, to purchase shares were excluded from the diluted EPS calculation, as the impact of their inclusion would have been anti-dilutive. Basic and diluted EPS are computed independently for each quarter and year-to-date period, and each period involves the use of different weighted-average share count figures. As a result, and after factoring the effect of rounding to the nearest cent per share, the sum of prior quarterly EPS figures may not equal year-to-date EPS. The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the nine-month period ended September 29, 2023 and the three and nine-month periods ended September 30, 2022, and as such 3.4 million shares for the nine-month period ended September 29, 2023 and 8.6 million for both the three and nine-month periods ended September 30, 2022 underlying the MCPS Series B were excluded from the calculation of diluted EPS and the related MCPS Series B dividends of $21 million for the nine-month period ended September 29, 2023 and $21 million and $64 million for the three and nine-month periods ended September 30, 2022, respectively, were included in the calculation of net earnings for diluted EPS. As of April 17, 2023, all outstanding shares of the MCPS Series B converted into 8.6 million shares of the Company’s common stock. The impact of the MCPS Series A calculated under the if-converted method was dilutive for the nine-month period ended September 30, 2022, and as such 4.0 million shares underlying the MCPS Series A were included in the calculation of diluted EPS. The related MCPS Series A dividends of $20 million for the nine-month period ended September 30, 2022 were excluded from the calculation of net earnings for diluted EPS. On April 15, 2022, all outstanding shares of the MCPS Series A converted into 11.0 million shares of the Company’s common stock. Refer to Note 15 for additional information about the MCPS Series A and B conversions. Information related to the calculation of net earnings per common share is summarized as follows ($ and shares in millions, except per share amounts): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Numerator: Net earnings $ 1,129 $ 1,572 $ 3,685 $ 4,977 MCPS dividends — (21) (21) (84) Net earnings attributable to common stockholders for Basic EPS 1,129 1,551 3,664 4,893 Adjustment for MCPS dividends for dilutive MCPS — — — 20 Net earnings attributable to common stockholders after assumed conversions for Diluted EPS $ 1,129 $ 1,551 $ 3,664 $ 4,913 Denominator: Weighted average common shares outstanding used in Basic EPS 739.4 728.5 735.4 723.8 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive restricted stock units (“RSUs”) and performance stock units (“PSUs”) 6.5 8.9 6.7 9.2 Weighted average MCPS converted shares — — — 4.0 Weighted average common shares outstanding used in Diluted EPS 745.9 737.4 742.1 737.0 Basic EPS $ 1.53 $ 2.13 $ 4.98 $ 6.76 Diluted EPS $ 1.51 $ 2.10 $ 4.94 $ 6.67

Revenue

Revenue	9 Months Ended
Revenue	Sep. 29, 2023
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and nine-month periods ended September 29, 2023 and September 30, 2022 ($ in millions) . Sales taxes and other usage-based taxes collected from customers are excluded from revenue. Biotechnology Life Sciences Diagnostics Environmental & Applied Solutions Total For the Three-Month Period Ended September 29, 2023: Geographical region: North America (a) $ 593 $ 728 $ 1,054 $ 599 $ 2,974 Western Europe 508 356 334 269 1,467 Other developed markets (b) 78 117 105 30 330 High-growth markets (c) 485 505 761 351 2,102 Total $ 1,664 $ 1,706 $ 2,254 $ 1,249 $ 6,873 Revenue type: Recurring $ 1,390 $ 1,062 $ 1,986 $ 744 $ 5,182 Nonrecurring 274 644 268 505 1,691 Total $ 1,664 $ 1,706 $ 2,254 $ 1,249 $ 6,873 For the Three-Month Period Ended September 30, 2022: Geographical region: North America (a) $ 723 $ 785 $ 1,397 $ 575 $ 3,480 Western Europe 599 314 388 240 1,541 Other developed markets (b) 71 118 122 28 339 High-growth markets (c) 660 506 772 365 2,303 Total $ 2,053 $ 1,723 $ 2,679 $ 1,208 $ 7,663 Revenue type: Recurring $ 1,662 $ 1,038 $ 2,396 $ 729 $ 5,825 Nonrecurring 391 685 283 479 1,838 Total $ 2,053 $ 1,723 $ 2,679 $ 1,208 $ 7,663 Biotechnology Life Sciences Diagnostics Environmental & Applied Solutions Total For the Nine-Month Period Ended September 29, 2023: Geographical region: North America (a) $ 1,822 $ 2,193 $ 3,160 $ 1,748 $ 8,923 Western Europe 1,839 1,095 1,119 830 4,883 Other developed markets (b) 229 369 322 90 1,010 High-growth markets (c) 1,523 1,554 2,260 1,044 6,381 Total $ 5,413 $ 5,211 $ 6,861 $ 3,712 $ 21,197 Revenue type: Recurring $ 4,435 $ 3,205 $ 6,056 $ 2,210 $ 15,906 Nonrecurring 978 2,006 805 1,502 5,291 Total $ 5,413 $ 5,211 $ 6,861 $ 3,712 $ 21,197 For the Nine-Month Period Ended September 30, 2022: Geographical region: North America (a) $ 2,303 $ 2,301 $ 3,938 $ 1,674 $ 10,216 Western Europe 1,938 982 1,365 775 5,060 Other developed markets (b) 244 366 361 92 1,063 High-growth markets (c) 2,050 1,441 2,220 1,052 6,763 Total $ 6,535 $ 5,090 $ 7,884 $ 3,593 $ 23,102 Revenue type: Recurring $ 5,267 $ 3,143 $ 7,067 $ 2,138 $ 17,615 Nonrecurring 1,268 1,947 817 1,455 5,487 Total $ 6,535 $ 5,090 $ 7,884 $ 3,593 $ 23,102 (a) The Company defines North America as the United States and Canada. (b ) The Company defines other developed markets as Japan, Australia and New Zealand. (c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets. The Company sells equipment to customers as well as consumables and services, some of which customers purchase on a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, chromatography resins used for research and bioprocessing, filters used in filtration, separation and purification processes and (prior to the Separation) cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a standalone basis, such as custom nucleic acids, genomics solutions and (prior to the Separation) water treatment solutions. The Company separates its goods and services between those typically sold to a customer on a recurring basis and those typically sold to a customer on a nonrecurring basis. Recurring revenue includes revenue from consumables, services and operating-type leases (“OTLs”). Nonrecurring revenue includes sales of equipment and sales-type leases (“STLs”). OTLs and STLs are included in the above revenue amounts. For the three-month periods ended September 29, 2023 and September 30, 2022, lease revenue was $125 million and $120 million, respectively. For the nine-month periods ended September 29, 2023 and September 30, 2022, lease revenue was $363 million and $361 million, respectively. Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. As of September 29, 2023, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $4.9 billion. The Company expects to recognize revenue on approximately 51% of the remaining performance obligations over the next 12 months, 27% over the subsequent 12 months, and the remainder recognized thereafter. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”) on the Consolidated Condensed Balance Sheets. Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as other current assets in the Consolidated Condensed Balance Sheets. The balance of contract assets as of September 29, 2023 and December 31, 2022 was $63 million and $90 million, respectively. The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities that are classified as either current or long-term in the Consolidated Condensed Balance Sheets based on the timing of when the Company expects to recognize revenue. As of both September 29, 2023 and December 31, 2022, contract liabilities were approximately $1.9 billion, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Revenue recognized during both the nine-month periods ended September 29, 2023 and September 30, 2022 that was included in the contract liability balance on December 31, 2022 and December 31, 2021, respectively, was approximately $1.2 billion. Contract assets and liabilities are reported on a net basis on the accompanying Consolidated Condensed Balance Sheets on a contract-by-contract basis at the end of each reporting period.

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 29, 2023
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company operates and reports its results in business segments consisting of the Biotechnology, Life Sciences, Diagnostics, and (prior to the Separation) Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs, including separation costs related to preparation for the separation of the Company’s Environmental & Applied Solutions business of $36 million and $101 million in the three and nine-month periods ended September 29, 2023, respectively, and other costs not considered part of management’s evaluation of reportable segment operating performance. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals. Segment results are shown below ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Sales: Biotechnology $ 1,664 $ 2,053 $ 5,413 $ 6,535 Life Sciences 1,706 1,723 5,211 5,090 Diagnostics 2,254 2,679 6,861 7,884 Environmental & Applied Solutions 1,249 1,208 3,712 3,593 Total $ 6,873 $ 7,663 $ 21,197 $ 23,102 Operating profit: Biotechnology $ 417 $ 691 $ 1,493 $ 2,315 Life Sciences 313 354 974 1,022 Diagnostics 539 761 1,640 2,447 Environmental & Applied Solutions 286 286 887 829 Other (117) (77) (333) (221) Total $ 1,438 $ 2,015 $ 4,661 $ 6,392

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 29, 2023
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The following table summarizes the Company’s effective tax rate: Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Effective tax rate 19.2 % 18.6 % 19.7 % 18.4 % The Company operates globally, including in certain jurisdictions with lower tax rates than the United States (“U.S.”) federal statutory rate. Therefore, the impact of operating in such jurisdictions contributes to a lower effective tax rate compared to the U.S. federal statutory tax rate. The effective tax rate for the three-month period ended September 29, 2023 differs from the U.S. federal statutory rate of 21.0% due to the geographic mix of earnings described above. Discrete tax benefits from excess tax benefits from stock-based compensation were offset by charges related to tax costs related to the separation of the Environmental & Applied Solutions business and changes in estimates associated with prior period uncertain tax positions. The effective tax rate for the nine-month period ended September 29, 2023 differs from the U.S. federal statutory rate of 21.0% principally due to the geographic mix of earnings described above, partially offset by net discrete tax charges of $13 million. Net discrete tax charges related primarily to tax costs related to the separation of the Environmental & Applied Solutions business, tax costs related to legal and operational actions taken to realign certain businesses and changes in estimates associated with prior period uncertain tax positions, partially offset by excess tax benefits from stock-based compensation and interest on prior year tax refunds. The net discrete charges increased the effective tax rate by 0.3% for the nine-month period ended September 29, 2023. The effective tax rate for the three-month period ended September 30, 2022 differs from the U.S. federal statutory rate of 21.0% principally due to the geographic mix of earnings described above and net discrete benefits of $3 million related primarily to excess tax benefits from stock-based compensation, partially offset by changes in estimates associated with prior period uncertain tax positions. The net discrete benefits reduced the effective tax rate by 0.2% for the three-month period ended September 30, 2022. The effective tax rate for the nine-month period ended September 30, 2022 differs from the U.S. federal statutory rate of 21.0% principally due the geographic mix of earnings described above and net discrete benefits of $52 million related primarily to excess tax benefits from stock-based compensation and changes in estimates associated with prior period uncertain tax positions. The net discrete benefits reduced the effective tax rate by 0.9% for the nine-month period ended September 30, 2022. In the fourth quarter of 2022, the U.S. Internal Revenue Service (“IRS”) proposed significant adjustments to the Company’s taxable income for the years 2016 through 2018 with respect to the deferral of tax on certain premium income related to the Company’s self-insurance programs. For income tax purposes, the recognition of premium income has been deferred in accordance with U.S. tax laws related to insurance. The IRS challenged the deferral of premium income for certain types of the Company’s self-insurance policies. The proposed adjustments would have increased the Company’s taxable income over the 2016 through 2018 periods by approximately $2.5 billion. In the first quarter of 2023, the Company settled these proposed adjustments with the IRS, although the audit is still open with respect to other matters for the 2016 through 2018 period. The impact of the settlement with respect to the Company’s self-insurance policies was not material to the Company’s financial statements, including cash flows and the effective tax rate. As the settlement with the IRS was specific to the audit period, the settlement does not preclude the IRS from proposing similar adjustments to the Company’s self-insurance programs with respect to periods subsequent to 2018. Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws. For a description of the Company’s significant tax matters, reference is made to the financial statements as of and for the year ended December 31, 2022 and Note 7 thereto included in the Company’s 2022 Annual Report.

Other Income (Expense), Net

Other Income (Expense), Net	9 Months Ended
Other Income (Expense), Net	Sep. 29, 2023
Other Income and Expenses [Abstract]
Other Income (Expense), Net	OTHER INCOME (EXPENSE), NET The following sets forth the components of the Company’s other income (expense), net ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Other components of net periodic benefit costs $ 1 $ 13 $ 6 $ 28 Investment gains (losses): Realized investment gains (losses) 120 27 120 91 Unrealized investment gains (losses) (168) (91) (178) (277) Total investment gains (losses) (48) (64) (58) (186) Total other income (expense), net $ (47) $ (51) $ (52) $ (158) Other Components of Net Periodic Benefit Costs The Company disaggregates the service cost component of net periodic benefit costs of noncontributory defined benefit pension plans and other postretirement employee benefit plans and presents the other components of net periodic benefit costs in other income (expense), net. These other components of net periodic benefit costs include the assumed rate of return on plan assets, partially offset by amortization of actuarial losses and interest. The Company’s net periodic benefit costs for the nine-month period ended September 30, 2022 included a settlement loss of $10 million ($9 million after-tax) as a result of the transfer of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third-party. Investment Gains (Losses)

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
Goodwill and Other Intangible Assets	Sep. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	GOODWILL AND OTHER INTANGIBLE ASSETS The following is a rollforward of the Company’s goodwill ($ in millions): Balance, December 31, 2022 $ 39,752 Adjustments due to finalization of purchase price allocations (2) Foreign currency translation and other (595) Balance, September 29, 2023 $ 39,155 The carrying value of goodwill by segment is summarized as follows ($ in millions): September 29, 2023 December 31, 2022 Biotechnology $ 21,643 $ 22,087 Life Sciences 8,227 8,314 Diagnostics 6,805 6,875 Environmental & Applied Solutions 2,480 2,476 Total $ 39,155 $ 39,752 The Company has not identified any “triggering” events which indicate an impairment of goodwill in 2023.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 29, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTSAccounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety. A summary of financial assets that are measured at fair value on a recurring basis were as follows ($ in millions): Balance Quoted Prices in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 29, 2023 December 31, 2022 September 29, 2023 December 31, 2022 September 29, 2023 December 31, 2022 September 29, 2023 December 31, 2022 Assets: Available-for-sale debt securities $ 4 $ 11 $ — $ — $ 4 $ 11 $ — $ — Investment in equity securities 444 315 131 16 — — — — Cross-currency swap derivative contracts 547 653 — — 547 653 — — Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated Condensed Balance Sheets, are measured at fair value using quoted prices reported by investment brokers and dealers based on the underlying terms of the security and comparison to similar securities traded on an active market. As of September 29, 2023 and December 31, 2022, available-for-sale debt securities primarily included U.S. Treasury Notes and corporate debt securities. The Company’s investments in equity securities consist of investments in publicly traded equity securities and investments in non-marketable equity securities. The publicly traded securities are classified as Level 1 in the fair value hierarchy as they are measured based on quotes in active markets. For the non-marketable equity securities, the Company estimates the fair value of the investments in equity securities based on the measurement alternative and adjusts for impairments and observable price changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). The Company’s investments in these equity securities are not classified in the fair value hierarchy due to the use of these measurement methods. Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting and are not subject to fair value measurement disclosures noted above. As of both September 29, 2023 and December 31, 2022, the Company’s equity method investments included investments in partnerships with a carrying value of approximately $1.5 billion. Refer to Note 8 for additional information on gains and losses on the Company’s investments including investments in the partnerships. The cross-currency swap derivative contracts are used to partially hedge the Company’s net investments in non-U.S. operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. The Company also uses cross-currency swap derivative contracts to hedge the exchange rate exposure from long-term debt issuances in a foreign currency other than the functional currency of the borrower. The cross-currency swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and current foreign currency exchange rates and forward curves as inputs. Refer to Note 12 for additional information. Fair Value of Other Financial Instruments The carrying amounts and fair values of the Company’s other financial instruments were as follows ($ in millions): September 29, 2023 December 31, 2022 Carrying Amount Fair Value Carrying Amount Fair Value Debt obligations: Notes payable and current portion of long-term debt $ 2,547 $ 2,534 $ 591 $ 584 Long-term debt 19,513 16,245 19,086 16,079 As of September 29, 2023 and December 31, 2022, short and long-term borrowings were categorized as Level 1. The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing. The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable generally approximate their carrying amounts due to the short-term maturities of these instruments.

Financing

Financing	9 Months Ended
Financing	Sep. 29, 2023
Debt Disclosure [Abstract]
Financing	FINANCING As of September 29, 2023, the Company was in compliance with all of its debt covenants. The components of the Company’s debt were as follows ($ in millions): Outstanding Amount Description and Aggregate Principal Amount September 29, 2023 December 31, 2022 Euro-denominated commercial paper (€1.9 billion) (e) $ 1,982 $ 2,013 0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”) (c) 590 584 1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”) (f) 951 962 2.2% senior unsecured notes due 11/15/2024 ($700 million) (the “2024 Biopharma Notes”) (b) 699 698 3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”) (f) 499 499 0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”) (b) 1,317 1,333 2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) (f) 844 854 0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) (d) 206 234 1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) (a) 632 639 0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) (b) 1,315 1,331 1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) (c) 232 230 2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”) (b) 796 796 2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) (f) 846 856 0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) (b) 1,841 1,863 0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) (d) 355 404 1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) (b) 1,307 1,323 3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”) (b) 891 890 4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”) (f) 499 499 1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) (b) 784 794 3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”) (b) 890 889 2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”) (f) 981 981 2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”) (f) 984 984 Other 15 21 Subtotal $ 19,456 $ 19,677 Veralto debt: 5.50% senior unsecured bonds due 9/18/2026 ($700 million) (the “2026 Veralto Bonds”) (g) 695 — 5.35% senior unsecured bonds due 9/18/2028 ($700 million) (the “2028 Veralto Bonds”) (g) 694 — 4.15% senior unsecured bonds due 9/19/2031 (€500 million) (the “2031 Veralto Bonds”) (g) 523 — 5.45% senior unsecured bonds due 9/18/2033 ($700 million) (the “2033 Veralto Bonds”) (g) 692 — Total Veralto debt $ 2,604 $ — Total debt 22,060 19,677 Less: currently payable (2,547) (591) Long-term debt $ 19,513 $ 19,086 (a) Issued by DH Europe Finance S.A. (“Danaher International”). (b) Issued by DH Europe Finance II S.a.r.l. (“Danaher International II”). (c) Issued by DH Switzerland Finance S.A. (“Danaher Switzerland”). (d) Issued by DH Japan Finance S.A. (“Danaher Japan”). (e) Issued by Danaher Corporation or Danaher International II. (f) Issued by Danaher Corporation. (g) Issued by Veralto Corporation. Debt discounts, premiums and debt issuance costs totaled $135 million and $118 million as of September 29, 2023 and December 31, 2022, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above. For additional details regarding the Company’s debt financing, refer to Note 14 of the Company’s financial statements as of and for the year ended December 31, 2022 included in the Company’s 2022 Annual Report. The Company has historically satisfied short-term liquidity needs that are not met through operating cash flow and available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs. As of September 29, 2023, borrowings outstanding under the Company’s euro-denominated commercial paper program had a weighted average annual interest rate of 4.0% and a weighted average remaining maturity of approximately 38 days. Revolving Credit Facility On August 11, 2023, the Company replaced its existing $5.0 billion u nsecured, multiyear revolving credit facility with a third amended and restated $5.0 billion unsecured, multiyear revolving credit facility (the “Credit Facility”) with a syndicate of lenders. The Credit Facility expires on August 11, 2028, subject to a one-year extension option at the request of Danaher and with the consent of the lenders. The Credit Facility also contains an expansion option permitting Danaher to request up to five increases of up to an aggregate additional $2.5 billion from lenders that elect to make such increase available, upon the satisfaction of certain conditions. No borrowings were outstanding under the existing credit facility at the time it was replaced with the Credit Facility. Borrowings under the Credit Facility bear interest as follows: (i) in the case of borrowings denominated in U.S. dollars, (1) Term Secured Overnight Financing Rate (“SOFR”) Loans (as defined in the Credit Facility) bear interest at a variable rate equal to the Term SOFR (as defined in the Credit Facility) plus a margin of between 58.5 and 101.5 basis points, depending on Danaher’s long-term debt credit rating; (2) Base Rate Committed Loans and Swing Line Loans (each as defined in the Credit Facility) bear interest at a variable rate equal to the highest of (a) the Federal funds rate (as published by the Federal Reserve Bank of New York from time to time) plus 1/2 of 1%, (b) Bank of America’s “prime rate” as publicly announced from time to time, (c) Term SOFR (based on one-month interest period plus 1%) and (d) 1%, plus in each case a margin of between 0 to 1.5 basis points depending on Danaher’s long-term debt credit rating; and (ii) in the case of borrowings denominated in an Alternative Currency (as defined in the Credit Facility), Alternative Currency Loans and Swing Line Loans (each as defined in the Credit Facility) bear interest at the applicable variable benchmark rate plus, in each case, a margin of between 58.5 and 101.5 basis points, depending on Danaher’s long-term debt credit rating. In no event will Term SOFR Loans, Swing Line Loans or Alternative Currency Loans bear interest at a rate lower than 0.0%. In addition, Danaher is required to pay a per annum facility fee of between 4.0 and 11.0 basis points (depending on Danaher’s long-term debt credit rating) based on the aggregate commitments under the Credit Facility, regardless of usage. The Credit Facility requires Danaher to maintain a Consolidated Leverage Ratio (as defined in the Credit Facility) of 0.65 to 1.00 or less. Borrowings under the Credit Facility are prepayable at Danaher’s option at any time in whole or in part without premium or penalty. Danaher’s obligations under the Credit Facility are unsecured. Danaher has unconditionally and irrevocably guaranteed the obligations of each of its subsidiaries in the event a subsidiary is named a borrower under the Credit Facility. The Credit Facility contains customary representations, warranties, conditions precedent, events of default, indemnities and affirmative and negative covenants. Danaher intends to use the Credit Facility for liquidity support for Danaher’s U.S. dollar and euro-denominated commercial paper programs and for general corporate purposes. Indebtedness Related to the Veralto Separation In September 2023, the Company received net cash distributions of approximately $2.6 billion from Veralto as partial consideration for the Company’s contribution of assets to Veralto in connection with the Separation. Veralto financed these cash payments through the issuance of approximately $2.6 billion of debt, consisting of $700 million aggregate principal amount of 5.50% senior unsecured bonds due 2026, $700 million aggregate principal amount of 5.35% senior unsecured bonds due 2028, $700 million aggregate principal amount of 5.45% senior unsecured bonds due 2033 and €500 million aggregate principal amount of 4.15% senior unsecured bonds due 2031 (collectively, the “Veralto Debt”). Danaher initially guaranteed the Veralto Debt, and the guarantee automatically terminated effective as of the Distribution Date. As of September 29, 2023, Veralto was a wholly-owned, consolidated subsidiary of the Company, and as a result, the Company’s Consolidated Balance Sheet as of September 29, 2023 includes the Veralto Debt. The transfer of the liabilities associated with the Veralto Debt, as well as all other assets and liabilities transferred to Veralto, will be reflected in the Company's financial statements in the fourth quarter of 2023. In addition, Veralto Corporation entered into a revolving credit agreement with a syndicate of lenders providing for a five-year $1.5 billion unsecured revolving credit facility (the “Veralto Credit Facility”). No amounts were outstanding under the Veralto Credit Facility at any time prior to the Separation. As of September 29, 2023, Veralto was in compliance with all covenants under the Veralto Credit Facility. Guarantors of Debt The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned finance subsidiaries: Danaher International, Danaher International II, Danaher Switzerland and Danaher Japan. All of the outstanding and future securities issued by each of these entities are or will be fully and unconditionally guaranteed by the Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness. In addition, prior to the Separation, the Company guaranteed the long-term debt issued by Veralto Corporation. This guarantee terminated as of the time of the Separation.

Hedging Transactions and Deriva

Hedging Transactions and Derivative Financial Instruments	9 Months Ended
Hedging Transactions and Derivative Financial Instruments	Sep. 29, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Hedging Transactions and Derivative Financial Instruments	HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS The Company uses cross-currency swap derivative contracts to partially hedge its net investments in non-U.S. operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. These contracts effectively convert U.S. dollar-denominated bonds to obligations denominated in Danish kroner, Japanese yen, euro and Swiss franc, and partially offset the impact of changes in currency rates on the Company’s foreign currency denominated net investments. These contracts also reduce the interest rate from the stated interest rates on the U.S. dollar-denominated debt to the interest rates of the swaps. The changes in the spot rate of these instruments are recorded in accumulated other comprehensive income (loss) in stockholders’ equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive income (loss). The interest income or expense from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from September 2025 to November 2032. The Company also uses cross-currency swap derivative contracts to hedge U.S. dollar-denominated long-term debt issuances in a foreign subsidiary whose functional currency is the euro against adverse movements in exchange rates between the U.S. dollar and the euro. These contracts effectively convert these U.S. dollar-denominated bonds to obligations denominated in euro. The changes in the fair value of these instruments are recorded in accumulated other comprehensive income (loss), with a reclassification from accumulated other comprehensive income (loss) to net earnings to offset the remeasurement of the hedged debt that is also recorded in net earnings. The interest income or expense from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from November 2024 to November 2049. The Company has also issued foreign currency denominated long-term debt as partial hedges of its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro, Japanese yen and Swiss franc. These foreign currency denominated long-term debt issuances are designated and qualify as nonderivative hedging instruments. Accordingly, the foreign currency translation of these debt instruments is recorded in accumulated other comprehensive income (loss), offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive income (loss). These instruments mature on dates ranging from October 2023 to May 2032. The Company used interest rate swap agreements to hedge the variability in cash flows due to changes in benchmark interest rates related to a portion of the U.S. debt the Company issued to fund the acquisition of Cytiva and a portion of the 2051 U.S. Notes. These contracts effectively fixed the interest rate for a portion of the Company’s U.S. dollar-denominated debt equal to the notional amount of the swaps to the rate specified in the interest rate swap agreements and were settled in November 2019 and December 2021, respectively. The changes in the fair value of these instruments were recorded in accumulated other comprehensive income (loss) prior to the issuance of the debt and are subsequently being reclassified to interest expense over the life of the related debt. The following table summarizes the notional values as of September 29, 2023 and September 30, 2022 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive income (“OCI”) for the three and nine-month periods ended September 29, 2023 and September 30, 2022 ($ in millions): Original Notional Amount Notional Amount Outstanding Gain (Loss) Recognized in OCI Amounts Reclassified from OCI For the Three-Month Period Ended September 29, 2023: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 28 $ — Foreign currency denominated debt 6,179 6,179 181 — Cash flow hedges: Cross-currency contracts 4,000 3,300 22 (102) Interest rate swaps 1,600 — — — Total $ 15,654 $ 12,479 $ 231 $ (102) For the Three-Month Period Ended September 30, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 127 $ — Foreign currency denominated debt 5,522 5,522 174 — Cash flow hedges: Cross-currency contracts 4,000 4,000 214 (240) Interest rate swaps 1,600 — — — Total $ 14,997 $ 12,522 $ 515 $ (240) For the Nine-Month Period Ended September 29, 2023: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ (38) $ — Foreign currency denominated debt 6,179 6,179 130 — Cash flow hedges: Cross-currency contracts 4,000 3,300 (68) (39) Interest rate swaps 1,600 — — 2 Total $ 15,654 $ 12,479 $ 24 $ (37) For the Nine-Month Period Ended September 30, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 394 $ — Foreign currency denominated debt 5,522 5,522 569 — Cash flow hedges: Cross-currency contracts 4,000 4,000 720 (580) Interest rate swaps 1,600 — — 2 Total $ 14,997 $ 12,522 $ 1,683 $ (578) Gains or losses related to the net investment hedges are classified as foreign currency translation adjustments in the schedule of changes in OCI in Note 15, as these items are attributable to the Company’s hedges of its net investment in foreign operations. Gains or losses related to the cash flow hedges are classified as cash flow hedge adjustments in the schedule of changes in OCI in Note 15. The amount reclassified from other comprehensive income (loss) for the cross-currency swap derivative contracts that are cash flow hedges of the Company’s U.S. dollar-denominated debt was equal to the remeasurement amount recorded in the three and nine-month periods on the hedged debt. The Company did not reclassify any other deferred gains or losses related to net investment hedges or cash flow hedges from accumulated other comprehensive income (loss) to earnings during the three and nine-month periods ended September 29, 2023 and September 30, 2022. In addition, the Company did not have any ineffectiveness related to net investment hedges or cash flow hedges during the three and nine-month periods ended September 29, 2023 and September 30, 2022, and, should they arise, any ineffective portions of the hedges would be reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in all other investing activities in the accompanying Consolidated Condensed Statements of Cash Flows. The cash inflows and outflows associated with the Company’s derivative contracts designated as cash flow hedges are classified in cash flows from operating activities in the accompanying Consolidated Condensed Statements of Cash Flows. The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Consolidated Condensed Balance Sheets as follows ($ in millions): September 29, 2023 December 31, 2022 Derivative assets: Other long-term assets $ 547 $ 653 Nonderivative hedging instruments: Notes payable and current portion of long-term debt 2,541 — Long-term debt 3,638 5,777 Amounts related to the Company’s derivatives expected to be reclassified from accumulated other comprehensive income (loss) to net earnings during the next 12 months, if interest rates and foreign exchange rates remain unchanged, are not significant.

Defined Benefit Plans

Defined Benefit Plans	9 Months Ended
Defined Benefit Plans	Sep. 29, 2023
Retirement Benefits [Abstract]
Defined Benefit Plans	DEFINED BENEFIT PLANS The following sets forth the components of the Company’s net periodic benefit costs of the noncontributory defined benefit pension plans and other postretirement employee benefit plans ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 U.S. pension benefits: Service cost $ — $ — $ — $ — Interest cost (25) (13) (73) (40) Expected return on plan assets 31 32 94 97 Amortization of actuarial loss (3) (8) (9) (26) Amortization of prior service cost (1) — (1) — Net periodic pension benefit $ 2 $ 11 $ 11 $ 31 Non-U.S. pension benefits: Service cost $ (8) $ (10) $ (24) $ (29) Interest cost (12) (6) (37) (18) Expected return on plan assets 10 10 28 28 Amortization of actuarial gain (loss) 2 — 6 (1) Amortization of prior service credit — 1 1 1 Settlement losses recognized — (1) — (11) Net periodic pension cost $ (8) $ (6) $ (26) $ (30) Other postretirement employee benefit plans: Service cost $ — $ — $ — $ — Interest cost (2) (1) (5) (2) Amortization of actuarial loss — (1) — (1) Amortization of prior service credit 1 — 2 1 Net periodic benefit cost $ (1) $ (2) $ (3) $ (2) The service cost component of net periodic benefit costs is presented in cost of goods sold and selling, general and administrative expenses while the other cost components are presented in other income (expense), net. The Company’s net periodic pension cost for the nine-month period ended September 30, 2022 included a settlement loss of $10 million as a result of the transfer of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third-party. Employer Contributions

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 29, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES The Company reviews the adequacy of its legal reserves on a quarterly basis and establishes reserves for loss contingencies that are both probable and reasonably estimable. For a further description of the Company’s litigation and contingencies, refer to Note 18 of the Company’s financial statements as of and for the year ended December 31, 2022 included in the Company’s 2022 Annual Report. In connection with the Separation and in accordance with the separation and distribution and related agreements Danaher and Veralto entered into, the Company agreed to indemnify Veralto and its affiliates against certain damages and expenses that might occur in the future. These indemnification obligations cover a variety of liabilities, including, but not limited to, employee and tax matters. The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly and appropriately maintained. Warranty periods depend on the nature of the product and range from the date of such sale up to twenty years. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain instances estimated property damage. As of September 29, 2023 and December 31, 2022, the Company had accrued warranty liabilities of $97 million and $95 million, respectively.

Stockholders' Equity and Stock-

Stockholders' Equity and Stock-based Compensation	9 Months Ended
Stockholders' Equity and Stock-based Compensation	Sep. 29, 2023
Share-Based Payment Arrangement [Abstract]
Stockholders' Equity and Stock-based Compensation	STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION Stockholders’ Equity On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. A s of September 29, 2023 , approximately 20 million shares remained available f or repurchase pursuant to the Repurchase Program. The following table summarizes the Company’s share activity (shares in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Preferred stock - shares issued: Balance, beginning of period — 1.7 1.7 3.4 Conversion of MCPS to common stock — — (1.7) (1.7) Balance, end of period — 1.7 — 1.7 Common stock - shares issued: Balance, beginning of period 879.5 868.4 869.3 855.7 Common stock-based compensation awards 0.7 0.5 2.3 2.2 Conversion of MCPS to common stock — — 8.6 11.0 Balance, end of period 880.2 868.9 880.2 868.9 As of April 17, 2023, all outstanding shares of the Company’s 5.00% MCPS Series B converted to common shares at a rate of 5.0175 common shares per share of preferred stock into an aggregate of 8.6 million shares of the Company’s common stock, pursuant to the terms of the Certificate of Designation governing the Series B Preferred Stock. On April 15, 2022, all outstanding shares of the Company’s 4.75% MCPS Series A converted to common shares at a rate of 6.6632 common shares per share of preferred stock into an aggregate of 11.0 million shares of the Company’s common stock, pursuant to the terms of the Certificate of Designation governing the Series A Preferred Stock. For additional information on the MCPS, refer to Note 19 in the Company’s 2022 Annual Report. Stock-Based Compensation For a full description of the Company’s stock-based compensation programs, refer to Note 19 of the Company’s financial statements as of and for the year ended December 31, 2022 included in the Company’s 2022 Annual Report. As of September 29, 2023, approximately 41 million shares of the Com pany’s common stock were reserved for issuance under the 2007 Omnibus Incentive Plan. The following information about the Company's stock-based compensation programs includes amounts for both the Company's and Veralto's employees. In connection with the Separation and in accordance with the employee matters agreement Danaher and Veralto have entered into, the Company has made certain adjustments to the exercise price and the number of stock-based compensation awards with the intention of preserving the intrinsic value of the awards immediately prior to the Separation. Stock-based compensation awards have been converted into awards of the company that employs t he employee post-separation, and Veralto has responsibility for the awards that were converted into Veralto awards. The adjustment to the Company’s stock-based compensation awards as a result of the Separation is not expected to have a significant impact to the Company’s stock compensation expense. Stock-based compensation disclosures reflecting the impact of the Separation will be included in the Company's Annual Report on Form 10-K for the year ending December 31, 2023. The following summarizes the components of the Company’s stock-based compensation expense ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 RSUs/PSUs: Pretax compensation expense $ 51 $ 52 $ 157 $ 156 Income tax benefit (11) (11) (32) (32) RSU/PSU expense, net of income taxes 40 41 125 124 Stock options: Pretax compensation expense 41 37 123 114 Income tax benefit (8) (7) (25) (23) Stock option expense, net of income taxes 33 30 98 91 Total stock-based compensation: Pretax compensation expense 92 89 280 270 Income tax benefit (19) (18) (57) (55) Total stock-based compensation expense, net of income taxes $ 73 $ 71 $ 223 $ 215 Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. As of September 29, 2023, $222 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately two years. As of September 29, 2023, $269 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately two years. Future compensation amounts will be adjusted for any changes in estimated forfeitures. Accumulated Other Comprehensive Income Accumulated other comprehensive income (loss) refers to certain gains and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings as these amounts are initially recorded as an adjustment to stockholders’ equity. Foreign currency translation adjustments generally relate to indefinite investments in non-U.S. subsidiaries, as well as the impact from the Company’s hedges of its net investment in foreign operations, including the Company’s cross-currency swap derivatives, net of any income tax impacts. The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Pension and Postretirement Plan Benefit Adjustments Cash Flow Hedge Adjustments Accumulated Comprehensive Income (Loss) For the Three-Month Period Ended September 29, 2023: Balance, June 30, 2023 $ (3,323) $ (341) $ 88 $ (3,576) Other comprehensive income (loss) before reclassifications: Increase (decrease) (296) — 22 (274) Income tax impact (7) — — (7) Other comprehensive income (loss) before reclassifications, net of income taxes (303) — 22 (281) Reclassification adjustments: Increase (decrease) — 1 (a) (102) (b) (101) Income tax impact — — (1) (1) Reclassification adjustments, net of income taxes — 1 (103) (102) Net other comprehensive income (loss), net of income taxes (303) 1 (81) (383) Balance, September 29, 2023 $ (3,626) $ (340) $ 7 $ (3,959) For the Three-Month Period Ended September 30, 2022: Balance, July 1, 2022 $ (2,324) $ (529) $ 108 $ (2,745) Other comprehensive income (loss) before reclassifications: Increase (decrease) (1,008) — 214 (794) Income tax impact (31) — (51) (82) Other comprehensive income (loss) before reclassifications, net of income taxes (1,039) — 163 (876) Reclassification adjustments: Increase (decrease) — 9 (a) (240) (b) (231) Income tax impact — (2) — (2) Reclassification adjustments, net of income taxes — 7 (240) (233) Net other comprehensive income (loss), net of income taxes (1,039) 7 (77) (1,109) Balance, September 30, 2022 $ (3,363) $ (522) $ 31 $ (3,854) Foreign Currency Translation Adjustments Pension and Postretirement Plan Benefit Adjustments Cash Flow Hedge Adjustments Accumulated Comprehensive Income (Loss) For the Nine-Month Period Ended September 29, 2023: Balance, December 31, 2022 $ (2,644) $ (341) $ 113 $ (2,872) Other comprehensive income (loss) before reclassifications: Increase (decrease) (991) — (68) (1,059) Income tax impact 9 — — 9 Other comprehensive income (loss) before reclassifications, net of income taxes (982) — (68) (1,050) Reclassification adjustments: Increase (decrease) — 1 (a) (37) (b) (36) Income tax impact — — (1) (1) Reclassification adjustments, net of income taxes — 1 (38) (37) Net other comprehensive income (loss), net of income taxes (982) 1 (106) (1,087) Balance, September 29, 2023 $ (3,626) $ (340) $ 7 $ (3,959) For the Nine-Month Period Ended September 30, 2022: Balance, December 31, 2021 $ (539) $ (550) $ 62 $ (1,027) Other comprehensive income (loss) before reclassifications: Increase (decrease) (2,729) — 720 (2,009) Income tax impact (95) — (173) (268) Other comprehensive income (loss) before reclassifications, net of income taxes (2,824) — 547 (2,277) Reclassification adjustments: Increase (decrease) — 37 (a) (578) (b) (541) Income tax impact — (9) — (9) Reclassification adjustments, net of income taxes — 28 (578) (550) Net other comprehensive income (loss), net of income taxes (2,824) 28 (31) (2,827) Balance, September 30, 2022 $ (3,363) $ (522) $ 31 $ (3,854) (a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic benefit cost (refer to Notes 8 and 13 for additional details). (b) Reflects reclassification to earnings related to cash flow hedges of certain long-term debt (refer to Note 12 for additional details).

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net earnings	$ 1,129	$ 1,572	$ 3,685	$ 4,977

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 29, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

General (Policies)

General (Policies)	9 Months Ended
General (Policies)	Sep. 29, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Standards Recently Adopted	Accounting Standards Recently Adopted —In August 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement
Operating Leases	Operating Leases —As of September 29, 2023 and December 31, 2022, operating lease right-of-use assets where the Company was the lessee were approximately $1.0 billion and are included within other long-term assets in the accompanying Consolidated Condensed Balance Sheets. The associated operating lease liabilities were approximately $1.1 billion as of September 29, 2023 and December 31, 2022, and are included in accrued expenses and other liabilities and other long-term liabilities.

Environmental & Applied Solut_2

Environmental & Applied Solutions Separation (Tables)	9 Months Ended
Environmental & Applied Solutions Separation (Tables)	Sep. 29, 2023
Discontinued Operations and Disposal Groups [Abstract]
Summary of the Environmental & Applied Solutions Business Sales and Operating Profit	Below is a summary of the Environmental & Applied Solutions business' sales and operating profit ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Sales $ 1,249 $ 1,208 $ 3,712 $ 3,593 Operating profit 286 286 887 829

Net Earnings Per Common Share (

Net Earnings Per Common Share (Tables)	9 Months Ended
Net Earnings Per Common Share (Tables)	Sep. 29, 2023
Earnings Per Share [Abstract]
Information Related to the Calculation of Net Earnings Per Common Share	Information related to the calculation of net earnings per common share is summarized as follows ($ and shares in millions, except per share amounts): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Numerator: Net earnings $ 1,129 $ 1,572 $ 3,685 $ 4,977 MCPS dividends — (21) (21) (84) Net earnings attributable to common stockholders for Basic EPS 1,129 1,551 3,664 4,893 Adjustment for MCPS dividends for dilutive MCPS — — — 20 Net earnings attributable to common stockholders after assumed conversions for Diluted EPS $ 1,129 $ 1,551 $ 3,664 $ 4,913 Denominator: Weighted average common shares outstanding used in Basic EPS 739.4 728.5 735.4 723.8 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive restricted stock units (“RSUs”) and performance stock units (“PSUs”) 6.5 8.9 6.7 9.2 Weighted average MCPS converted shares — — — 4.0 Weighted average common shares outstanding used in Diluted EPS 745.9 737.4 742.1 737.0 Basic EPS $ 1.53 $ 2.13 $ 4.98 $ 6.76 Diluted EPS $ 1.51 $ 2.10 $ 4.94 $ 6.67

Revenue (Tables)

Revenue (Tables)	9 Months Ended
Revenue (Tables)	Sep. 29, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and nine-month periods ended September 29, 2023 and September 30, 2022 ($ in millions) . Sales taxes and other usage-based taxes collected from customers are excluded from revenue. Biotechnology Life Sciences Diagnostics Environmental & Applied Solutions Total For the Three-Month Period Ended September 29, 2023: Geographical region: North America (a) $ 593 $ 728 $ 1,054 $ 599 $ 2,974 Western Europe 508 356 334 269 1,467 Other developed markets (b) 78 117 105 30 330 High-growth markets (c) 485 505 761 351 2,102 Total $ 1,664 $ 1,706 $ 2,254 $ 1,249 $ 6,873 Revenue type: Recurring $ 1,390 $ 1,062 $ 1,986 $ 744 $ 5,182 Nonrecurring 274 644 268 505 1,691 Total $ 1,664 $ 1,706 $ 2,254 $ 1,249 $ 6,873 For the Three-Month Period Ended September 30, 2022: Geographical region: North America (a) $ 723 $ 785 $ 1,397 $ 575 $ 3,480 Western Europe 599 314 388 240 1,541 Other developed markets (b) 71 118 122 28 339 High-growth markets (c) 660 506 772 365 2,303 Total $ 2,053 $ 1,723 $ 2,679 $ 1,208 $ 7,663 Revenue type: Recurring $ 1,662 $ 1,038 $ 2,396 $ 729 $ 5,825 Nonrecurring 391 685 283 479 1,838 Total $ 2,053 $ 1,723 $ 2,679 $ 1,208 $ 7,663 Biotechnology Life Sciences Diagnostics Environmental & Applied Solutions Total For the Nine-Month Period Ended September 29, 2023: Geographical region: North America (a) $ 1,822 $ 2,193 $ 3,160 $ 1,748 $ 8,923 Western Europe 1,839 1,095 1,119 830 4,883 Other developed markets (b) 229 369 322 90 1,010 High-growth markets (c) 1,523 1,554 2,260 1,044 6,381 Total $ 5,413 $ 5,211 $ 6,861 $ 3,712 $ 21,197 Revenue type: Recurring $ 4,435 $ 3,205 $ 6,056 $ 2,210 $ 15,906 Nonrecurring 978 2,006 805 1,502 5,291 Total $ 5,413 $ 5,211 $ 6,861 $ 3,712 $ 21,197 For the Nine-Month Period Ended September 30, 2022: Geographical region: North America (a) $ 2,303 $ 2,301 $ 3,938 $ 1,674 $ 10,216 Western Europe 1,938 982 1,365 775 5,060 Other developed markets (b) 244 366 361 92 1,063 High-growth markets (c) 2,050 1,441 2,220 1,052 6,763 Total $ 6,535 $ 5,090 $ 7,884 $ 3,593 $ 23,102 Revenue type: Recurring $ 5,267 $ 3,143 $ 7,067 $ 2,138 $ 17,615 Nonrecurring 1,268 1,947 817 1,455 5,487 Total $ 6,535 $ 5,090 $ 7,884 $ 3,593 $ 23,102 (a) The Company defines North America as the United States and Canada. (b ) The Company defines other developed markets as Japan, Australia and New Zealand. (c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Sep. 29, 2023
Segment Reporting [Abstract]
Segment Results	Segment results are shown below ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Sales: Biotechnology $ 1,664 $ 2,053 $ 5,413 $ 6,535 Life Sciences 1,706 1,723 5,211 5,090 Diagnostics 2,254 2,679 6,861 7,884 Environmental & Applied Solutions 1,249 1,208 3,712 3,593 Total $ 6,873 $ 7,663 $ 21,197 $ 23,102 Operating profit: Biotechnology $ 417 $ 691 $ 1,493 $ 2,315 Life Sciences 313 354 974 1,022 Diagnostics 539 761 1,640 2,447 Environmental & Applied Solutions 286 286 887 829 Other (117) (77) (333) (221) Total $ 1,438 $ 2,015 $ 4,661 $ 6,392

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
Income Taxes (Tables)	Sep. 29, 2023
Income Tax Disclosure [Abstract]
Summary of Effective Income Tax Rate	The following table summarizes the Company’s effective tax rate: Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Effective tax rate 19.2 % 18.6 % 19.7 % 18.4 %

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	9 Months Ended
Other Income (Expense), Net (Tables)	Sep. 29, 2023
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)	The following sets forth the components of the Company’s other income (expense), net ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Other components of net periodic benefit costs $ 1 $ 13 $ 6 $ 28 Investment gains (losses): Realized investment gains (losses) 120 27 120 91 Unrealized investment gains (losses) (168) (91) (178) (277) Total investment gains (losses) (48) (64) (58) (186) Total other income (expense), net $ (47) $ (51) $ (52) $ (158)

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
Goodwill and Other Intangible Assets (Tables)	Sep. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Rollforward of Goodwill	The following is a rollforward of the Company’s goodwill ($ in millions): Balance, December 31, 2022 $ 39,752 Adjustments due to finalization of purchase price allocations (2) Foreign currency translation and other (595) Balance, September 29, 2023 $ 39,155 The carrying value of goodwill by segment is summarized as follows ($ in millions): September 29, 2023 December 31, 2022 Biotechnology $ 21,643 $ 22,087 Life Sciences 8,227 8,314 Diagnostics 6,805 6,875 Environmental & Applied Solutions 2,480 2,476 Total $ 39,155 $ 39,752
Goodwill by Segment	The following is a rollforward of the Company’s goodwill ($ in millions): Balance, December 31, 2022 $ 39,752 Adjustments due to finalization of purchase price allocations (2) Foreign currency translation and other (595) Balance, September 29, 2023 $ 39,155 The carrying value of goodwill by segment is summarized as follows ($ in millions): September 29, 2023 December 31, 2022 Biotechnology $ 21,643 $ 22,087 Life Sciences 8,227 8,314 Diagnostics 6,805 6,875 Environmental & Applied Solutions 2,480 2,476 Total $ 39,155 $ 39,752

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 29, 2023
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value	A summary of financial assets that are measured at fair value on a recurring basis were as follows ($ in millions): Balance Quoted Prices in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 29, 2023 December 31, 2022 September 29, 2023 December 31, 2022 September 29, 2023 December 31, 2022 September 29, 2023 December 31, 2022 Assets: Available-for-sale debt securities $ 4 $ 11 $ — $ — $ 4 $ 11 $ — $ — Investment in equity securities 444 315 131 16 — — — — Cross-currency swap derivative contracts 547 653 — — 547 653 — —
Carrying Amounts and Fair Values of Financial Instruments	The carrying amounts and fair values of the Company’s other financial instruments were as follows ($ in millions): September 29, 2023 December 31, 2022 Carrying Amount Fair Value Carrying Amount Fair Value Debt obligations: Notes payable and current portion of long-term debt $ 2,547 $ 2,534 $ 591 $ 584 Long-term debt 19,513 16,245 19,086 16,079

Financing (Tables)

Financing (Tables)	9 Months Ended
Financing (Tables)	Sep. 29, 2023
Debt Disclosure [Abstract]
Components of Debt	The components of the Company’s debt were as follows ($ in millions): Outstanding Amount Description and Aggregate Principal Amount September 29, 2023 December 31, 2022 Euro-denominated commercial paper (€1.9 billion) (e) $ 1,982 $ 2,013 0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”) (c) 590 584 1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”) (f) 951 962 2.2% senior unsecured notes due 11/15/2024 ($700 million) (the “2024 Biopharma Notes”) (b) 699 698 3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”) (f) 499 499 0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”) (b) 1,317 1,333 2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) (f) 844 854 0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) (d) 206 234 1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) (a) 632 639 0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) (b) 1,315 1,331 1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) (c) 232 230 2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”) (b) 796 796 2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) (f) 846 856 0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) (b) 1,841 1,863 0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) (d) 355 404 1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) (b) 1,307 1,323 3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”) (b) 891 890 4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”) (f) 499 499 1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) (b) 784 794 3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”) (b) 890 889 2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”) (f) 981 981 2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”) (f) 984 984 Other 15 21 Subtotal $ 19,456 $ 19,677 Veralto debt: 5.50% senior unsecured bonds due 9/18/2026 ($700 million) (the “2026 Veralto Bonds”) (g) 695 — 5.35% senior unsecured bonds due 9/18/2028 ($700 million) (the “2028 Veralto Bonds”) (g) 694 — 4.15% senior unsecured bonds due 9/19/2031 (€500 million) (the “2031 Veralto Bonds”) (g) 523 — 5.45% senior unsecured bonds due 9/18/2033 ($700 million) (the “2033 Veralto Bonds”) (g) 692 — Total Veralto debt $ 2,604 $ — Total debt 22,060 19,677 Less: currently payable (2,547) (591) Long-term debt $ 19,513 $ 19,086 (a) Issued by DH Europe Finance S.A. (“Danaher International”). (b) Issued by DH Europe Finance II S.a.r.l. (“Danaher International II”). (c) Issued by DH Switzerland Finance S.A. (“Danaher Switzerland”). (d) Issued by DH Japan Finance S.A. (“Danaher Japan”). (e) Issued by Danaher Corporation or Danaher International II. (f) Issued by Danaher Corporation. (g) Issued by Veralto Corporation.

Hedging Transactions and Deri_2

Hedging Transactions and Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 29, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	The following table summarizes the notional values as of September 29, 2023 and September 30, 2022 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive income (“OCI”) for the three and nine-month periods ended September 29, 2023 and September 30, 2022 ($ in millions): Original Notional Amount Notional Amount Outstanding Gain (Loss) Recognized in OCI Amounts Reclassified from OCI For the Three-Month Period Ended September 29, 2023: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 28 $ — Foreign currency denominated debt 6,179 6,179 181 — Cash flow hedges: Cross-currency contracts 4,000 3,300 22 (102) Interest rate swaps 1,600 — — — Total $ 15,654 $ 12,479 $ 231 $ (102) For the Three-Month Period Ended September 30, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 127 $ — Foreign currency denominated debt 5,522 5,522 174 — Cash flow hedges: Cross-currency contracts 4,000 4,000 214 (240) Interest rate swaps 1,600 — — — Total $ 14,997 $ 12,522 $ 515 $ (240) For the Nine-Month Period Ended September 29, 2023: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ (38) $ — Foreign currency denominated debt 6,179 6,179 130 — Cash flow hedges: Cross-currency contracts 4,000 3,300 (68) (39) Interest rate swaps 1,600 — — 2 Total $ 15,654 $ 12,479 $ 24 $ (37) For the Nine-Month Period Ended September 30, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 394 $ — Foreign currency denominated debt 5,522 5,522 569 — Cash flow hedges: Cross-currency contracts 4,000 4,000 720 (580) Interest rate swaps 1,600 — — 2 Total $ 14,997 $ 12,522 $ 1,683 $ (578)
Schedule of Notional Amounts of Outstanding Derivative Positions	The following table summarizes the notional values as of September 29, 2023 and September 30, 2022 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive income (“OCI”) for the three and nine-month periods ended September 29, 2023 and September 30, 2022 ($ in millions): Original Notional Amount Notional Amount Outstanding Gain (Loss) Recognized in OCI Amounts Reclassified from OCI For the Three-Month Period Ended September 29, 2023: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 28 $ — Foreign currency denominated debt 6,179 6,179 181 — Cash flow hedges: Cross-currency contracts 4,000 3,300 22 (102) Interest rate swaps 1,600 — — — Total $ 15,654 $ 12,479 $ 231 $ (102) For the Three-Month Period Ended September 30, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 127 $ — Foreign currency denominated debt 5,522 5,522 174 — Cash flow hedges: Cross-currency contracts 4,000 4,000 214 (240) Interest rate swaps 1,600 — — — Total $ 14,997 $ 12,522 $ 515 $ (240) For the Nine-Month Period Ended September 29, 2023: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ (38) $ — Foreign currency denominated debt 6,179 6,179 130 — Cash flow hedges: Cross-currency contracts 4,000 3,300 (68) (39) Interest rate swaps 1,600 — — 2 Total $ 15,654 $ 12,479 $ 24 $ (37) For the Nine-Month Period Ended September 30, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 394 $ — Foreign currency denominated debt 5,522 5,522 569 — Cash flow hedges: Cross-currency contracts 4,000 4,000 720 (580) Interest rate swaps 1,600 — — 2 Total $ 14,997 $ 12,522 $ 1,683 $ (578)
Schedule of Derivative and Non Derivative Instruments in Consolidated Condensed Balance Sheets	The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Consolidated Condensed Balance Sheets as follows ($ in millions): September 29, 2023 December 31, 2022 Derivative assets: Other long-term assets $ 547 $ 653 Nonderivative hedging instruments: Notes payable and current portion of long-term debt 2,541 — Long-term debt 3,638 5,777

Defined Benefit Plans (Tables)

Defined Benefit Plans (Tables)	9 Months Ended
Defined Benefit Plans (Tables)	Sep. 29, 2023
Retirement Benefits [Abstract]
Schedule of Net Benefit Costs	The following sets forth the components of the Company’s net periodic benefit costs of the noncontributory defined benefit pension plans and other postretirement employee benefit plans ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 U.S. pension benefits: Service cost $ — $ — $ — $ — Interest cost (25) (13) (73) (40) Expected return on plan assets 31 32 94 97 Amortization of actuarial loss (3) (8) (9) (26) Amortization of prior service cost (1) — (1) — Net periodic pension benefit $ 2 $ 11 $ 11 $ 31 Non-U.S. pension benefits: Service cost $ (8) $ (10) $ (24) $ (29) Interest cost (12) (6) (37) (18) Expected return on plan assets 10 10 28 28 Amortization of actuarial gain (loss) 2 — 6 (1) Amortization of prior service credit — 1 1 1 Settlement losses recognized — (1) — (11) Net periodic pension cost $ (8) $ (6) $ (26) $ (30) Other postretirement employee benefit plans: Service cost $ — $ — $ — $ — Interest cost (2) (1) (5) (2) Amortization of actuarial loss — (1) — (1) Amortization of prior service credit 1 — 2 1 Net periodic benefit cost $ (1) $ (2) $ (3) $ (2)

Stockholders' Equity and Stoc_2

Stockholders' Equity and Stock-based Compensation (Tables)	9 Months Ended
Stockholders' Equity and Stock-based Compensation (Tables)	Sep. 29, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Share Activity	The following table summarizes the Company’s share activity (shares in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Preferred stock - shares issued: Balance, beginning of period — 1.7 1.7 3.4 Conversion of MCPS to common stock — — (1.7) (1.7) Balance, end of period — 1.7 — 1.7 Common stock - shares issued: Balance, beginning of period 879.5 868.4 869.3 855.7 Common stock-based compensation awards 0.7 0.5 2.3 2.2 Conversion of MCPS to common stock — — 8.6 11.0 Balance, end of period 880.2 868.9 880.2 868.9
Components of Stock-Based Compensation Program	The following summarizes the components of the Company’s stock-based compensation expense ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 RSUs/PSUs: Pretax compensation expense $ 51 $ 52 $ 157 $ 156 Income tax benefit (11) (11) (32) (32) RSU/PSU expense, net of income taxes 40 41 125 124 Stock options: Pretax compensation expense 41 37 123 114 Income tax benefit (8) (7) (25) (23) Stock option expense, net of income taxes 33 30 98 91 Total stock-based compensation: Pretax compensation expense 92 89 280 270 Income tax benefit (19) (18) (57) (55) Total stock-based compensation expense, net of income taxes $ 73 $ 71 $ 223 $ 215
Components of Accumulated Other Comprehensive Income (Loss)	The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Pension and Postretirement Plan Benefit Adjustments Cash Flow Hedge Adjustments Accumulated Comprehensive Income (Loss) For the Three-Month Period Ended September 29, 2023: Balance, June 30, 2023 $ (3,323) $ (341) $ 88 $ (3,576) Other comprehensive income (loss) before reclassifications: Increase (decrease) (296) — 22 (274) Income tax impact (7) — — (7) Other comprehensive income (loss) before reclassifications, net of income taxes (303) — 22 (281) Reclassification adjustments: Increase (decrease) — 1 (a) (102) (b) (101) Income tax impact — — (1) (1) Reclassification adjustments, net of income taxes — 1 (103) (102) Net other comprehensive income (loss), net of income taxes (303) 1 (81) (383) Balance, September 29, 2023 $ (3,626) $ (340) $ 7 $ (3,959) For the Three-Month Period Ended September 30, 2022: Balance, July 1, 2022 $ (2,324) $ (529) $ 108 $ (2,745) Other comprehensive income (loss) before reclassifications: Increase (decrease) (1,008) — 214 (794) Income tax impact (31) — (51) (82) Other comprehensive income (loss) before reclassifications, net of income taxes (1,039) — 163 (876) Reclassification adjustments: Increase (decrease) — 9 (a) (240) (b) (231) Income tax impact — (2) — (2) Reclassification adjustments, net of income taxes — 7 (240) (233) Net other comprehensive income (loss), net of income taxes (1,039) 7 (77) (1,109) Balance, September 30, 2022 $ (3,363) $ (522) $ 31 $ (3,854) Foreign Currency Translation Adjustments Pension and Postretirement Plan Benefit Adjustments Cash Flow Hedge Adjustments Accumulated Comprehensive Income (Loss) For the Nine-Month Period Ended September 29, 2023: Balance, December 31, 2022 $ (2,644) $ (341) $ 113 $ (2,872) Other comprehensive income (loss) before reclassifications: Increase (decrease) (991) — (68) (1,059) Income tax impact 9 — — 9 Other comprehensive income (loss) before reclassifications, net of income taxes (982) — (68) (1,050) Reclassification adjustments: Increase (decrease) — 1 (a) (37) (b) (36) Income tax impact — — (1) (1) Reclassification adjustments, net of income taxes — 1 (38) (37) Net other comprehensive income (loss), net of income taxes (982) 1 (106) (1,087) Balance, September 29, 2023 $ (3,626) $ (340) $ 7 $ (3,959) For the Nine-Month Period Ended September 30, 2022: Balance, December 31, 2021 $ (539) $ (550) $ 62 $ (1,027) Other comprehensive income (loss) before reclassifications: Increase (decrease) (2,729) — 720 (2,009) Income tax impact (95) — (173) (268) Other comprehensive income (loss) before reclassifications, net of income taxes (2,824) — 547 (2,277) Reclassification adjustments: Increase (decrease) — 37 (a) (578) (b) (541) Income tax impact — (9) — (9) Reclassification adjustments, net of income taxes — 28 (578) (550) Net other comprehensive income (loss), net of income taxes (2,824) 28 (31) (2,827) Balance, September 30, 2022 $ (3,363) $ (522) $ 31 $ (3,854) (a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic benefit cost (refer to Notes 8 and 13 for additional details). (b) Reflects reclassification to earnings related to cash flow hedges of certain long-term debt (refer to Note 12 for additional details).

General (Operating Leases) (Det

General (Operating Leases) (Details) - USD ($) $ in Billions	Sep. 29, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating lease, right-of-use assets	$ 1	$ 1
Operating lease, liabilities	$ 1.1	$ 1.1

Pending Acquisition (Narrative)

Pending Acquisition (Narrative) (Details) - Abcam- Pending Acquisition £ in Millions, $ in Billions		12 Months Ended
	Aug. 28, 2023 USD ($)	Dec. 31, 2022 GBP (£)
Business Acquisition [Line Items]
Expected purchase price of acquisition \| $	$ 5.7
Revenue reported by acquired entity for last annual period \| £		£ 362

Environmental & Applied Solut_3

Environmental & Applied Solutions Separation (Narrative) (Details) $ in Millions		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 13, 2023	Sep. 29, 2023 USD ($)	Sep. 29, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 29, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales			$ 6,873	$ 7,663	$ 21,197	$ 23,102
Environmental & Applied Solutions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales							$ 4,800
Business separation costs			36		101
Business separation costs, net of tax			31		90
Veralto
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash consideration from Veralto prior to distribution date		$ 2,600
Total Veralto debt
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate principal amount		$ 2,600	$ 2,600		$ 2,600
Common stock \| Veralto
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shares of common stock of new entity received by shareholder for number of shares outstanding of distribution	0.3333

Environmental & Applied Solut_4

Environmental & Applied Solutions Separation (Summary of the Environmental & Applied Solutions Business Sales and Operating Profit) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales	$ 6,873	$ 7,663	$ 21,197	$ 23,102
Operating profit	1,438	2,015	4,661	6,392
Environmental & Applied Solutions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales					$ 4,800
Operating segments \| Environmental & Applied Solutions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales	1,249	1,208	3,712	3,593
Operating profit	$ 286	$ 286	$ 887	$ 829

Net Earnings Per Common Share_2

Net Earnings Per Common Share (Narrative) (Details) - USD ($) shares in Thousands, $ in Millions			3 Months Ended		9 Months Ended
	Apr. 17, 2023	Apr. 15, 2022	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Mandatory convertible preferred stock dividends			$ 0	$ 21	$ 21	$ 84
Dilutive MCPS shares included in computation of earnings per share (in shares)			0	0	0	4,000
MCPS Series B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)				8,600	3,400	8,600
MCPS Series A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive MCPS shares included in computation of earnings per share (in shares)						4,000
Common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)			2,500	538	3,200	1,100
Preferred stock \| MCPS Series B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Mandatory convertible preferred stock dividends				$ 21	$ 21	$ 64
Conversion of MCPS to common stock (in shares)	8,600
Preferred stock \| MCPS Series A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Mandatory convertible preferred stock dividends						$ 20
Conversion of MCPS to common stock (in shares)		11,000

Net Earnings Per Common Share_3

Net Earnings Per Common Share (Components of Basic and Diluted Earnings per Share from Continuing Operations) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Numerator
Net earnings	$ 1,129	$ 1,572	$ 3,685	$ 4,977
MCPS dividends	0	(21)	(21)	(84)
Net earnings attributable to common stockholders	1,129	1,551	3,664	4,893
Adjustment for MCPS dividends for dilutive MCPS	0	0	0	20
Net earnings attributable to common stockholders after assumed conversions for Diluted EPS	$ 1,129	$ 1,551	$ 3,664	$ 4,913
Denominator
Weighted average common shares outstanding used in Basic EPS (in shares)	739.4	728.5	735.4	723.8
Assumed exercise of dilutive options and vesting of dilutive restricted stock units (“RSUs”) and performance stock units (“PSUs”) (in shares)	6.5	8.9	6.7	9.2
Weighted average MCPS converted shares (in shares)	0	0	0	4
Weighted average common shares outstanding used in Diluted EPS (in shares)	745.9	737.4	742.1	737
Basic (in usd per share)	$ 1.53	$ 2.13	$ 4.98	$ 6.76
Diluted (in usd per share)	$ 1.51	$ 2.10	$ 4.94	$ 6.67	[1]

[1]Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.

Revenue (Disaggregation of Reve

Revenue (Disaggregation of Revenue by Geographical Region) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 6,873	$ 7,663	$ 21,197	$ 23,102
Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	5,182	5,825	15,906	17,615
Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	1,691	1,838	5,291	5,487
North America
Disaggregation of Revenue [Line Items]
Revenue	2,974	3,480	8,923	10,216
Western Europe
Disaggregation of Revenue [Line Items]
Revenue	1,467	1,541	4,883	5,060
Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	330	339	1,010	1,063
High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	2,102	2,303	6,381	6,763
Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Revenue					$ 4,800
Operating segments \| Biotechnology
Disaggregation of Revenue [Line Items]
Revenue	1,664	2,053	5,413	6,535
Operating segments \| Biotechnology \| Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	1,390	1,662	4,435	5,267
Operating segments \| Biotechnology \| Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	274	391	978	1,268
Operating segments \| Biotechnology \| North America
Disaggregation of Revenue [Line Items]
Revenue	593	723	1,822	2,303
Operating segments \| Biotechnology \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue	508	599	1,839	1,938
Operating segments \| Biotechnology \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	78	71	229	244
Operating segments \| Biotechnology \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	485	660	1,523	2,050
Operating segments \| Life Sciences
Disaggregation of Revenue [Line Items]
Revenue	1,706	1,723	5,211	5,090
Operating segments \| Life Sciences \| Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	1,062	1,038	3,205	3,143
Operating segments \| Life Sciences \| Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	644	685	2,006	1,947
Operating segments \| Life Sciences \| North America
Disaggregation of Revenue [Line Items]
Revenue	728	785	2,193	2,301
Operating segments \| Life Sciences \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue	356	314	1,095	982
Operating segments \| Life Sciences \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	117	118	369	366
Operating segments \| Life Sciences \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	505	506	1,554	1,441
Operating segments \| Diagnostics
Disaggregation of Revenue [Line Items]
Revenue	2,254	2,679	6,861	7,884
Operating segments \| Diagnostics \| Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	1,986	2,396	6,056	7,067
Operating segments \| Diagnostics \| Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	268	283	805	817
Operating segments \| Diagnostics \| North America
Disaggregation of Revenue [Line Items]
Revenue	1,054	1,397	3,160	3,938
Operating segments \| Diagnostics \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue	334	388	1,119	1,365
Operating segments \| Diagnostics \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	105	122	322	361
Operating segments \| Diagnostics \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	761	772	2,260	2,220
Operating segments \| Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Revenue	1,249	1,208	3,712	3,593
Operating segments \| Environmental & Applied Solutions \| Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	744	729	2,210	2,138
Operating segments \| Environmental & Applied Solutions \| Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	505	479	1,502	1,455
Operating segments \| Environmental & Applied Solutions \| North America
Disaggregation of Revenue [Line Items]
Revenue	599	575	1,748	1,674
Operating segments \| Environmental & Applied Solutions \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue	269	240	830	775
Operating segments \| Environmental & Applied Solutions \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	30	28	90	92
Operating segments \| Environmental & Applied Solutions \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	$ 351	$ 365	$ 1,044	$ 1,052

Revenue (Narrative) (Details)

Revenue (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Revenue (Narrative) (Details) - USD ($) $ in Millions	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue, OTLs and STLs	$ 125	$ 120	$ 363	$ 361
Contract with customer, assets, net	63		63		$ 90
Contract with customer, liabilities	$ 1,900		1,900		$ 1,900
Contract with customer, liabilities, revenue recognized			$ 1,200	$ 1,200

Revenue (Performance Obligation

Revenue (Performance Obligations) (Details) $ in Billions	Sep. 29, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 4.9
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-09-30
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	51%
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-09-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	27%
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months

Segment Information (Narrative)

Segment Information (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 29, 2023	Sep. 29, 2023
Environmental & Applied Solutions
Segment Reporting Information [Line Items]
Business separation costs	$ 36	$ 101

Segment Information (Segment Re

Segment Information (Segment Results) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Sales	$ 6,873	$ 7,663	$ 21,197	$ 23,102
Operating profit	1,438	2,015	4,661	6,392
Other
Segment Reporting Information [Line Items]
Operating profit	(117)	(77)	(333)	(221)
Biotechnology \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,664	2,053	5,413	6,535
Operating profit	417	691	1,493	2,315
Life Sciences \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,706	1,723	5,211	5,090
Operating profit	313	354	974	1,022
Diagnostics \| Operating segments
Segment Reporting Information [Line Items]
Sales	2,254	2,679	6,861	7,884
Operating profit	539	761	1,640	2,447
Environmental & Applied Solutions
Segment Reporting Information [Line Items]
Sales					$ 4,800
Environmental & Applied Solutions \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,249	1,208	3,712	3,593
Operating profit	$ 286	$ 286	$ 887	$ 829

Income Taxes (Summary of Danahe

Income Taxes (Summary of Danaher's Effective Income Tax Rate) (Details)	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	19.20%	18.60%	19.70%	18.40%

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Sep. 29, 2023	Dec. 31, 2022	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Federal statutory income tax rate, percent	21%		21%	21%	21%
Net tax charges (benefits), impact, amount			$ (3)	$ 13	$ (52)
Net tax charges (benefits), impact percentage			(0.20%)	0.30%	(0.90%)
Domestic Tax Authority \| Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Proposed adjustments to taxable income, self-insurance, other		$ 2,500

Other Income (Expense), Net (Sc

Other Income (Expense), Net (Schedule of Other Income (Expense)) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Other Income and Expenses [Abstract]
Other components of net periodic benefit costs	$ 1	$ 13	$ 6	$ 28
Investment gains (losses):
Realized investment gains (losses)	120	27	120	91
Unrealized investment gains (losses)	(168)	(91)	(178)	(277)
Total investment gains (losses)	(48)	(64)	(58)	(186)
Total other income (expense), net	$ (47)	$ (51)	$ (52)	$ (158)

Other Income (Expense), Net (Na

Other Income (Expense), Net (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Equity method investment, impairment	$ 46
Equity method investment, impairment, after tax	$ 35
Foreign Plan \| Defined benefit pension plans
Defined Benefit Plan Disclosure [Line Items]
Settlement loss		$ 10
Settlement loss, after tax		$ 9

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Rollforward of Goodwill) (Details) $ in Millions	9 Months Ended
	Sep. 29, 2023 USD ($)
Goodwill [Roll Forward]
Balance, beginning of period	$ 39,752
Adjustments due to finalization of purchase price allocations	(2)
Foreign currency translation and other	(595)
Balance, end of period	$ 39,155

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Goodwill by Segment) (Details) - USD ($) $ in Millions	Sep. 29, 2023	Dec. 31, 2022
Goodwill [Line Items]
Total goodwill	$ 39,155	$ 39,752
Operating segments \| Biotechnology
Goodwill [Line Items]
Total goodwill	21,643	22,087
Operating segments \| Life Sciences
Goodwill [Line Items]
Total goodwill	8,227	8,314
Operating segments \| Diagnostics
Goodwill [Line Items]
Total goodwill	6,805	6,875
Operating segments \| Environmental & Applied Solutions
Goodwill [Line Items]
Total goodwill	$ 2,480	$ 2,476

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 29, 2023	Sep. 29, 2023	Sep. 30, 2022
Property, Plant and Equipment [Line Items]
Impairment charges	$ 6	$ 40	$ 9
Facility
Property, Plant and Equipment [Line Items]
Impairment charges		$ 14

Fair Value Measurements (Financ

Fair Value Measurements (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Sep. 29, 2023	Dec. 31, 2022
Assets:
Available-for-sale debt securities	$ 4	$ 11
Investment in equity securities	444	315
Cross-currency swap derivative contracts	547	653
Quoted Prices in Active Market (Level 1)
Assets:
Available-for-sale debt securities	0	0
Investment in equity securities	131	16
Cross-currency swap derivative contracts	0	0
Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale debt securities	4	11
Investment in equity securities	0	0
Cross-currency swap derivative contracts	547	653
Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale debt securities	0	0
Investment in equity securities	0	0
Cross-currency swap derivative contracts	$ 0	$ 0

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Billions	Sep. 29, 2023	Dec. 31, 2022
Partnership
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity method investments	$ 1.5	$ 1.5

Fair Value Measurements (Carryi

Fair Value Measurements (Carrying Amounts and Fair Values of Other Financial Instruments) (Details) - USD ($) $ in Millions	Sep. 29, 2023	Dec. 31, 2022
Carrying Amount
Debt obligations:
Notes payable and current portion of long-term debt	$ 2,547	$ 591
Long-term debt	19,513	19,086
Fair Value
Debt obligations:
Notes payable and current portion of long-term debt	2,534	584
Long-term debt	$ 16,245	$ 16,079

Financing (Components of Debt)

Financing (Components of Debt) (Details) € in Millions, SFr in Millions, $ in Millions, ¥ in Billions	Sep. 29, 2023 USD ($)	Sep. 29, 2023 EUR (€)	Sep. 29, 2023 CHF (SFr)	Sep. 29, 2023 JPY (¥)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 JPY (¥)
Debt Instrument [Line Items]
Subtotal	$ 22,060				$ 19,677
Less: currently payable	(2,547)				(591)
Long-term debt	19,513				19,086
Other
Debt Instrument [Line Items]
Subtotal	15				21
Subtotal
Debt Instrument [Line Items]
Subtotal	19,456				19,677
Total Veralto debt
Debt Instrument [Line Items]
Subtotal	2,604				0
Aggregate principal amount	2,600
Commercial paper \| Euro-denominated commercial paper
Debt Instrument [Line Items]
Subtotal	1,982	€ 1,900			2,013	€ 1,900
Senior notes \| 1.7% senior notes due 2024
Debt Instrument [Line Items]
Subtotal	$ 951				$ 962
Interest rate of debt instrument	1.70%	1.70%	1.70%	1.70%	1.70%	1.70%	1.70%	1.70%
Aggregate principal amount \| €		€ 900				€ 900
Senior notes \| 2.2% senior notes due 2024
Debt Instrument [Line Items]
Subtotal	$ 699				$ 698
Interest rate of debt instrument	2.20%	2.20%	2.20%	2.20%	2.20%	2.20%	2.20%	2.20%
Aggregate principal amount	$ 700				$ 700
Senior notes \| 3.35% senior notes due 2025
Debt Instrument [Line Items]
Subtotal	$ 499				$ 499
Interest rate of debt instrument	3.35%	3.35%	3.35%	3.35%	3.35%	3.35%	3.35%	3.35%
Aggregate principal amount	$ 500				$ 500
Senior notes \| 0.2% senior notes due 2026
Debt Instrument [Line Items]
Subtotal	$ 1,317				$ 1,333
Interest rate of debt instrument	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%
Aggregate principal amount \| €		€ 1,300				€ 1,300
Senior notes \| 2.1% senior notes due 2026
Debt Instrument [Line Items]
Subtotal	$ 844				$ 854
Interest rate of debt instrument	2.10%	2.10%	2.10%	2.10%	2.10%	2.10%	2.10%	2.10%
Aggregate principal amount \| €		€ 800				€ 800
Senior notes \| 0.3% senior notes due 2027
Debt Instrument [Line Items]
Subtotal	$ 206				$ 234
Interest rate of debt instrument	0.30%	0.30%	0.30%	0.30%	0.30%	0.30%	0.30%	0.30%
Aggregate principal amount \| ¥				¥ 30.8				¥ 30.8
Senior notes \| 1.2% senior notes due 2027
Debt Instrument [Line Items]
Subtotal	$ 632				$ 639
Interest rate of debt instrument	1.20%	1.20%	1.20%	1.20%	1.20%	1.20%	1.20%	1.20%
Aggregate principal amount \| €		€ 600				€ 600
Senior notes \| 0.45% senior notes due 2028
Debt Instrument [Line Items]
Subtotal	$ 1,315				$ 1,331
Interest rate of debt instrument	0.45%	0.45%	0.45%	0.45%	0.45%	0.45%	0.45%	0.45%
Aggregate principal amount \| €		€ 1,300				€ 1,300
Senior notes \| 2.6% senior notes due 2029
Debt Instrument [Line Items]
Subtotal	$ 796				$ 796
Interest rate of debt instrument	2.60%	2.60%	2.60%	2.60%	2.60%	2.60%	2.60%	2.60%
Aggregate principal amount	$ 800				$ 800
Senior notes \| 2.5% senior notes due 2030
Debt Instrument [Line Items]
Subtotal	$ 846				$ 856
Interest rate of debt instrument	2.50%	2.50%	2.50%	2.50%	2.50%	2.50%	2.50%	2.50%
Aggregate principal amount \| €		€ 800				€ 800
Senior notes \| 0.75% senior notes due 2031
Debt Instrument [Line Items]
Subtotal	$ 1,841				$ 1,863
Interest rate of debt instrument	0.75%	0.75%	0.75%	0.75%	0.75%	0.75%	0.75%	0.75%
Aggregate principal amount \| €		€ 1,800				€ 1,800
Senior notes \| 0.65% senior notes due 2032
Debt Instrument [Line Items]
Subtotal	$ 355				$ 404
Interest rate of debt instrument	0.65%	0.65%	0.65%	0.65%	0.65%	0.65%	0.65%	0.65%
Aggregate principal amount \| ¥				¥ 53.2				¥ 53.2
Senior notes \| 1.35% senior notes due 2039
Debt Instrument [Line Items]
Subtotal	$ 1,307				$ 1,323
Interest rate of debt instrument	1.35%	1.35%	1.35%	1.35%	1.35%	1.35%	1.35%	1.35%
Aggregate principal amount \| €		€ 1,300				€ 1,300
Senior notes \| 3.25% senior notes due 2039
Debt Instrument [Line Items]
Subtotal	$ 891				$ 890
Interest rate of debt instrument	3.25%	3.25%	3.25%	3.25%	3.25%	3.25%	3.25%	3.25%
Aggregate principal amount	$ 900				$ 900
Senior notes \| 4.375% senior notes due 2045
Debt Instrument [Line Items]
Subtotal	$ 499				$ 499
Interest rate of debt instrument	4.375%	4.375%	4.375%	4.375%	4.375%	4.375%	4.375%	4.375%
Aggregate principal amount	$ 500				$ 500
Senior notes \| 1.8% senior notes due 2049
Debt Instrument [Line Items]
Subtotal	$ 784				$ 794
Interest rate of debt instrument	1.80%	1.80%	1.80%	1.80%	1.80%	1.80%	1.80%	1.80%
Aggregate principal amount \| €		€ 750				€ 750
Senior notes \| 3.4% senior notes due 2049
Debt Instrument [Line Items]
Subtotal	$ 890				$ 889
Interest rate of debt instrument	3.40%	3.40%	3.40%	3.40%	3.40%	3.40%	3.40%	3.40%
Aggregate principal amount	$ 900				$ 900
Senior notes \| 2.6% senior notes due 2050
Debt Instrument [Line Items]
Subtotal	$ 981				$ 981
Interest rate of debt instrument	2.60%	2.60%	2.60%	2.60%	2.60%	2.60%	2.60%	2.60%
Aggregate principal amount	$ 1,000				$ 1,000
Senior notes \| 2.8% senior unsecured notes due 2051
Debt Instrument [Line Items]
Subtotal	$ 984				$ 984
Interest rate of debt instrument	2.80%	2.80%	2.80%	2.80%	2.80%	2.80%	2.80%	2.80%
Aggregate principal amount	$ 1,000				$ 1,000
Bonds \| 0.5% senior bonds due 2023
Debt Instrument [Line Items]
Subtotal	$ 590				$ 584
Interest rate of debt instrument	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%
Aggregate principal amount \| SFr			SFr 540				SFr 540
Bonds \| 1.125% senior bonds due 2028
Debt Instrument [Line Items]
Subtotal	$ 232				$ 230
Interest rate of debt instrument	1.125%	1.125%	1.125%	1.125%	1.125%	1.125%	1.125%	1.125%
Aggregate principal amount \| SFr			SFr 210				SFr 210
Bonds \| 5.50% senior unsecured Veralto bonds due 2026
Debt Instrument [Line Items]
Subtotal	$ 695				$ 0
Interest rate of debt instrument	5.50%	5.50%	5.50%	5.50%
Aggregate principal amount	$ 700
Bonds \| 5.35% senior unsecured Veralto bonds due 2028
Debt Instrument [Line Items]
Subtotal	$ 694				0
Interest rate of debt instrument	5.35%	5.35%	5.35%	5.35%
Aggregate principal amount	$ 700
Bonds \| 4.15% senior unsecured Veralto bonds due 2031
Debt Instrument [Line Items]
Subtotal	$ 523				0
Interest rate of debt instrument	4.15%	4.15%	4.15%	4.15%
Aggregate principal amount \| €		€ 500
Bonds \| 5.45% senior unsecured Veralto bonds due 2033
Debt Instrument [Line Items]
Subtotal	$ 692				$ 0
Interest rate of debt instrument	5.45%	5.45%	5.45%	5.45%
Aggregate principal amount	$ 700

Financing (Narrative) (Details)

Financing (Narrative) (Details) € in Millions			1 Months Ended
Financing (Narrative) (Details) € in Millions	Sep. 29, 2023 USD ($)	Aug. 11, 2023 USD ($)	Sep. 29, 2023 USD ($)	Sep. 29, 2023 EUR (€)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Debt discounts, premiums and debt issuance costs	$ 135,000,000		$ 135,000,000		$ 118,000,000
Veralto
Debt Instrument [Line Items]
Cash consideration from Veralto prior to distribution date			$ 2,600,000,000
Euro-denominated commercial paper \| Commercial paper
Debt Instrument [Line Items]
Weighted average interest rate of long-term debt, interest rate	4%		4%	4%
Weighted average maturity of long-term debt, at point in time	38 days
Multiyear Credit Facility, Superseded \| Revolving credit facility
Debt Instrument [Line Items]
Borrowings outstanding		$ 0
Multiyear Credit Facility, Superseded \| Revolving credit facility \| Line of credit
Debt Instrument [Line Items]
Line of credit facility		$ 5,000,000,000
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Debt Rate, Condition Two
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate \| Debt Rate, Condition One
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Fed funds rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.05%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Minimum
Debt Instrument [Line Items]
Line of credit facility, commitment fee percentage		0.04%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Minimum \| Debt Rate, Condition Two
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Minimum \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.585%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Maximum
Debt Instrument [Line Items]
Line of credit facility, commitment fee percentage		0.11%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Maximum \| Debt Rate, Condition Two
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.015%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Maximum \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.015%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Line of credit
Debt Instrument [Line Items]
Line of credit facility		$ 5,000,000,000
Extension option, period		1 year
Line of credit facility additional borrowing capacity		$ 2,500,000,000
Consolidated Leverage Ratio		0.65
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Alternative Currency Loans \| Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.585%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Alternative Currency Loans \| Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.015%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Swing Line Loans \| Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.585%
Third Amended and Restated Multiyear Credit Facility \| Revolving credit facility \| Swing Line Loans \| Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.015%
5.50% senior unsecured Veralto bonds due 2026 \| Bonds
Debt Instrument [Line Items]
Aggregate principal amount	$ 700,000,000		$ 700,000,000
Interest rate of debt instrument	5.50%		5.50%	5.50%
5.35% senior unsecured Veralto bonds due 2028 \| Bonds
Debt Instrument [Line Items]
Aggregate principal amount	$ 700,000,000		$ 700,000,000
Interest rate of debt instrument	5.35%		5.35%	5.35%
5.45% senior unsecured Veralto bonds due 2033 \| Bonds
Debt Instrument [Line Items]
Aggregate principal amount	$ 700,000,000		$ 700,000,000
Interest rate of debt instrument	5.45%		5.45%	5.45%
4.15% senior unsecured Veralto bonds due 2031 \| Bonds
Debt Instrument [Line Items]
Aggregate principal amount \| €				€ 500
Interest rate of debt instrument	4.15%		4.15%	4.15%
Veralto Credit Facility \| Revolving credit facility
Debt Instrument [Line Items]
Line of credit facility	$ 1,500,000,000		$ 1,500,000,000
Borrowings outstanding	0		0
Total Veralto debt
Debt Instrument [Line Items]
Aggregate principal amount	$ 2,600,000,000		$ 2,600,000,000

Hedging Transactions and Deri_3

Hedging Transactions and Derivative Financial Instruments (Summary of Notional Values and Pretax Impact in Fair Values of Net Investment Hedges and Cash Flow Hedges) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Amounts Reclassified from OCI	$ 101	$ 231	$ 36	$ 541
Net investment hedges \| Cross-currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, original notional amount	3,875	3,875	3,875	3,875
Derivative, notional amount outstanding	3,000	3,000	3,000	3,000
Gain (Loss) Recognized in OCI	28	127	(38)	394
Amounts Reclassified from OCI	0	0	0	0
Net investment hedges \| Foreign currency denominated debt
Derivative Instruments, Gain (Loss) [Line Items]
Nonderivative, notional amount	6,179	5,522	6,179	5,522
Net investment hedges, gain (loss), recognized in OCI	181	174	130	569
Amounts Reclassified from OCI	0	0	0	0
Cash flow hedges \| Cross-currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, original notional amount	4,000	4,000	4,000	4,000
Derivative, notional amount outstanding	3,300	4,000	3,300	4,000
Gain (Loss) Recognized in OCI	22	214	(68)	720
Amounts Reclassified from OCI	(102)	(240)	(39)	(580)
Cash flow hedges \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, original notional amount	1,600	1,600	1,600	1,600
Derivative, notional amount outstanding	0	0	0	0
Gain (Loss) Recognized in OCI	0	0	0	0
Amounts Reclassified from OCI	0	0	2	2
Cash flow and net investment hedges
Derivative Instruments, Gain (Loss) [Line Items]
Original Notional Amount	15,654	14,997	15,654	14,997
Notional Amount Outstanding	12,479	12,522	12,479	12,522
Gain (Loss) Recognized in OCI	231	515	24	1,683
Amounts Reclassified from OCI	$ (102)	$ (240)	$ (37)	$ (578)

Hedging Transactions and Deri_4

Hedging Transactions and Derivative Financial Instruments (Derivative and Nonderivative Debt Instruments) (Details) - USD ($) $ in Millions	Sep. 29, 2023	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other long-term assets	Other long-term assets
Net investment hedges
Derivatives, Fair Value [Line Items]
Derivative assets	$ 547	$ 653
Net investment hedges \| Notes payable and current portion of long-term debt
Derivatives, Fair Value [Line Items]
Nonderivative hedging instruments	2,541	0
Net investment hedges \| Long-term debt
Derivatives, Fair Value [Line Items]
Nonderivative hedging instruments	$ 3,638	$ 5,777

Defined Benefit Plans (Componen

Defined Benefit Plans (Components of Net Periodic Benefit Cost of Defined Benefit Pension Plans) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Defined benefit pension plans \| U.S. pension benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0	$ 0	$ 0
Interest cost	(25)	(13)	(73)	(40)
Expected return on plan assets	31	32	94	97
Amortization of actuarial gain (loss)	(3)	(8)	(9)	(26)
Amortization of prior service cost (credit)	(1)	0	(1)	0
Net periodic benefit (cost)	2	11	11	31
Defined benefit pension plans \| Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	(8)	(10)	(24)	(29)
Interest cost	(12)	(6)	(37)	(18)
Expected return on plan assets	10	10	28	28
Amortization of actuarial gain (loss)	2	0	6	(1)
Amortization of prior service cost (credit)	0	1	1	1
Settlement losses recognized	0	(1)	0	(11)
Net periodic benefit (cost)	(8)	(6)	(26)	(30)
Other postretirement benefit plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	0	0
Interest cost	(2)	(1)	(5)	(2)
Amortization of actuarial gain (loss)	0	(1)	0	(1)
Amortization of prior service cost (credit)	1	0	2	1
Net periodic benefit (cost)	$ (1)	$ (2)	$ (3)	$ (2)

Defined Benefit Plans (Narrativ

Defined Benefit Plans (Narrative) (Details) - Defined benefit pension plans - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 29, 2023
Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Settlement loss	$ 10
Expected future employer contributions, current fiscal year		$ 39
U.S. pension benefits
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions, current fiscal year		$ 10

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2023	Dec. 31, 2022
Accrued warranty liabilities	$ 97	$ 95
Maximum
Standard product warranty period	20 years

Stockholders' Equity and Stoc_3

Stockholders' Equity and Stock-based Compensation (Narrative) (Details) $ in Millions			9 Months Ended	12 Months Ended
	Apr. 17, 2023 shares	Apr. 15, 2022 shares	Sep. 29, 2023 USD ($) shares	Dec. 31, 2022	Jul. 16, 2013 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized shares to be repurchased (in shares)					20,000,000
Remaining number of shares authorized to be repurchased (in shares)			20,000,000
Common shares reserved for issuance under the 2007 Omnibus Incentive Plan (in shares)			41,000,000
RSU/PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost \| $			$ 222
Weighted average period for cost to be recognized			2 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost \| $			$ 269
Weighted average period for cost to be recognized			2 years
Preferred stock \| Series B Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, dividend rate, percent	5%			5%
Preferred stock, convertible, conversion rate	5.0175
Conversion of MCPS to common stock (in shares)	8,600,000
Preferred stock \| Preferred stock series A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, dividend rate, percent		4.75%
Preferred stock, convertible, conversion rate		6.6632
Conversion of MCPS to common stock (in shares)		11,000,000

Stockholders' Equity and Stoc_4

Stockholders' Equity and Stock-based Compensation (Summary of Share Activity) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Preferred stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period	0	1.7	1.7	3.4
Balance, end of period	0	1.7	0	1.7
Preferred stock \| Conversion of MCPS to common stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of MCPS to common stock (in shares)	0	0	(1.7)	(1.7)
Common stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period	879.5	868.4	869.3	855.7
Common stock-based compensation awards	0.7	0.5	2.3	2.2
Balance, end of period	880.2	868.9	880.2	868.9
Common stock \| Conversion of MCPS to common stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of MCPS to common stock (in shares)	0	0	8.6	11

Stockholders' Equity and Stoc_5

Stockholders' Equity and Stock-based Compensation (Components of Stock-Based Compensation Program) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	$ 92	$ 89	$ 280	$ 270
Income tax benefit	(19)	(18)	(57)	(55)
Total stock-based compensation expense, net of income taxes	73	71	223	215
RSU/PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	51	52	157	156
Income tax benefit	(11)	(11)	(32)	(32)
Total stock-based compensation expense, net of income taxes	40	41	125	124
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	41	37	123	114
Income tax benefit	(8)	(7)	(25)	(23)
Total stock-based compensation expense, net of income taxes	$ 33	$ 30	$ 98	$ 91

Stockholders' Equity and Stoc_6

Stockholders' Equity and Stock-based Compensation (Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ (3,576)	$ (2,745)	$ (2,872)	$ (1,027)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)	(274)	(794)	(1,059)	(2,009)
Income tax impact	(7)	(82)	9	(268)
Other comprehensive income (loss) before reclassifications, net of income taxes	(281)	(876)	(1,050)	(2,277)
Reclassification adjustments:
Increase (decrease)	(101)	(231)	(36)	(541)
Income tax impact	(1)	(2)	(1)	(9)
Reclassification adjustments, net of income taxes	(102)	(233)	(37)	(550)
Total other comprehensive income (loss), net of income taxes	(383)	(1,109)	(1,087)	(2,827)
Ending balance	(3,959)	(3,854)	(3,959)	(3,854)
Foreign Currency Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(3,323)	(2,324)	(2,644)	(539)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)	(296)	(1,008)	(991)	(2,729)
Income tax impact	(7)	(31)	9	(95)
Other comprehensive income (loss) before reclassifications, net of income taxes	(303)	(1,039)	(982)	(2,824)
Reclassification adjustments:
Increase (decrease)	0	0	0	0
Income tax impact	0	0	0	0
Reclassification adjustments, net of income taxes	0	0	0	0
Total other comprehensive income (loss), net of income taxes	(303)	(1,039)	(982)	(2,824)
Ending balance	(3,626)	(3,363)	(3,626)	(3,363)
Pension and Postretirement Plan Benefit Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(341)	(529)	(341)	(550)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)	0	0	0	0
Income tax impact	0	0	0	0
Other comprehensive income (loss) before reclassifications, net of income taxes	0	0	0	0
Reclassification adjustments:
Increase (decrease)	1	9	1	37
Income tax impact	0	(2)	0	(9)
Reclassification adjustments, net of income taxes	1	7	1	28
Total other comprehensive income (loss), net of income taxes	1	7	1	28
Ending balance	(340)	(522)	(340)	(522)
Cash Flow Hedge Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	88	108	113	62
Other comprehensive income (loss) before reclassifications:
Increase (decrease)	22	214	(68)	720
Income tax impact	0	(51)	0	(173)
Other comprehensive income (loss) before reclassifications, net of income taxes	22	163	(68)	547
Reclassification adjustments:
Increase (decrease)	(102)	(240)	(37)	(578)
Income tax impact	(1)	0	(1)	0
Reclassification adjustments, net of income taxes	(103)	(240)	(38)	(578)
Total other comprehensive income (loss), net of income taxes	(81)	(77)	(106)	(31)
Ending balance	$ 7	$ 31	$ 7	$ 31